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The term point-of-care (POC) testing refers to laboratory tests performed near the 
patient, as opposed to a clinical laboratory setting. The aim of POC testing is to 
generate fast test results that facilitate accurate diagnosis and the initiation of proper 
treatment. POC testing is intended to improve patient outcomes and make laboratory 
testing available in settings where it has previously been unavailable. The measurement 
procedures (MPs) used for POC testing can be either simple test strips or complex 
analytical systems. In general, the MPs are more or less fully automated and often 
require few steps after sample collection before the test results are obtained. Since POC 
testing is usually performed outside the central laboratories, it is likely to be operated 
by persons who have not been trained as laboratory scientists, such as doctors, nurses, 
other healthcare professionals, or even the patients themselves.  
POC testing is the fastest-growing part of laboratory testing and makes up a notable 
share of the in vitro diagnostic medical device market. While POC testing eliminates 
some of the more problematic steps in the testing process, such as transportation of 
samples and distribution of test results, new challenges are introduced. Specifically, 
concerns regarding the test quality of POC testing have emerged, however, they can be 
addressed through the quality management of POC testing. In Norway, users of POC 
testing participate in the Norwegian Organization for Quality Improvement of 
Laboratory Examinations (Noklus), which provides a quality management system, 
including external quality assurance (EQA), covering the total testing process.  
Being a fundamental part of the EQA scheme, the EQA material must have 
characteristics that allow for evaluating the different MPs and their accuracy, precision, 
and calibration traceability, as well as provide a collective assessment of the 
laboratories, evaluating their reproducibility, standardization, and overall 
harmonization. The EQA material must possess a range of qualities to fulfill these 
requirements, the most important being commutability.  
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The aim of this thesis was to evaluate the effect of participating in an EQA organization 
and to evaluate the MPs and EQA material used to improve the participants’ analytical 
quality.  
In papers I and II, the aim was to evaluate whether the analytical performance of POC 
testing was influenced by participation in a quality improvement system over time. The 
factors related to good participant performance were also addressed. The analytes 
included in the two studies were urine albumin (u-albumin), C-reactive protein (CRP), 
glucose, and hemoglobin (Hb). Results from EQA schemes at Noklus were assessed, 
15 and 19 EQA schemes from 1998 to 2012 and 2006 to 2015, respectively. In paper 
II, logistic regression was performed to enable assessment of which characteristics 
predicted good participant performance. The average numbers of participants in the 
EQA schemes were 1159, 2134, 2357, and 2271 for u-albumin, CRP, glucose, and Hb, 
respectively. The results from the two studies showed a gradual increase in the 
percentage of participants with good performance. Furthermore, paper II showed that 
performing weekly internal quality control, performing the laboratory analysis ten or 
more times per week, using recommended MPs, and having operators that were 
qualified in laboratory medicine were all predictors of good participant performance in 
the EQAs.  
In paper III, the aim was to assess whether Noklus’ in-house whole blood EQA material 
for CRP, glucose, and Hb was commutable for the most frequently used POC MPs in 
Norway and assess the possibility of using a common target value for each of the three 
analytes. The study was performed following the guideline of the Clinical and 
Laboratory Standards Institute, EP14-A3 evaluation of commutability of processed 
samples, 3rd edition. The EQA material was pooled stabilized EDTA venous whole 
blood containing different concentrations of CRP, glucose, and Hb. The EQA material 
and native routine patient samples were analyzed using 17 POC and 3 hospital MPs. 
Deming regression with 95% prediction intervals for each MP comparison was used 
for assessing commutability. The evaluation showed that the EQA material was 
commutable for all the CRP and Hb POC MPs and all glucose POC MPs at the lowest 
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concentration (126.0 mg/dL (7.0 mmol/L)) and for the three glucose POC MPs at all 
concentrations.  
In conclusion, the studies in this thesis have revealed that systematic participation in a 
quality management system for POC testing in primary healthcare can improve the 
analytical quality of u-albumin, CRP, Hb, and glucose measurements. The whole blood 
EQA material used was commutable for all CRP and Hb MPs, and for approximately 
half of the glucose MPs used in primary healthcare in Norway. Both participant and 
MP evaluations can now be performed for these participants and MPs. 
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Accuracy: How close a single measurement value is to a real value. Accuracy is related 
to both the trueness and precision of a measurement value.  
Measurement error: Measured value minus a reference value. 
Random measurement error: How the measurement error between replicates varies 
unpredictably. The random error can qualitatively be expressed as precision. 
Precision: The closeness of agreement between replicate measurement values obtained 
under specific conditions. Precision is quantitively expressed as imprecision such as 
standard deviation or in percentage as the coefficient of variation under specific 
conditions.   
The specific conditions associated with precision/imprecision are repeatability, 
intermediate precision, and reproducibility, listed with respect to an increasing degree 
of variability. The specific conditions may also be divided into imprecision within one 
laboratory (compromising the repeatability and intermediate precision) and 
imprecision between laboratories (reproducibility).  
Repeatability: Replicate measurements on the same or similar object under the same 
set of conditions including the same measurement procedure, same operators, same 
conditions, and same location. The replicates are measured over a short period of time, 
usually the same day, (within-series variation).  
Intermediate precision: Replicate measurements on the same or similar object under 
the same set of conditions including the same measurement procedure, and same 
location, but may also involve changes in condition. The replicates are measured over 
an extended time-period, (within-laboratory variation).  
Reproducibility: Replicate measurement on the same or similar object under a different 
set of conditions including different measurement procedures, different operators, and 
different locations, (between-laboratory variation).  
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Trueness: Closeness of agreement between the average of a number of replicates 
measurement values and a reference value. Trueness is inversely related to bias.  
Bias/systematic measurement error: A measurement error which in replicate 
measurements is constant or varies in a predictable manner.  
Confidence interval: An interval associated with a confidence level representing the 
degree of uncertainty of the calculated value.  
Prediction interval: An interval where a future value is most likely to fall.  
Standardization: That measurement results are traceable, via calibration, to a higher-
order reference material or a reference measurement procedure. 
Harmonization: Measurement results being equivalent without traceability to a 
reference measurement procedure and not emphasizing the process to achieve 
equivalent results. 
Reference measurement procedure: A measurement procedure yielding measurement 
results fit for intended use when assessing measurement trueness obtained from other 
measurement procedures.  
Reference material: A material which is adequately homogenous and stable and 
established as fit for intended use in a measurement. 
CRM: A reference material accompanied by a certificate from an authoritative body 
providing specified property values, its associated uncertainty, and a statement of its 
traceability.  
Calibration hierarchy: A sequence of calibrations from a reference to a final measuring 
system. 
Primary measurement procedure: A measurement procedure acquiring the highest 
metrological characteristics, i.e., affecting both the estimate of the measurand and any 
uncertainty of this estimate (reported in SI units), additionally, the measurement 
procedure’s operation is described in detail and fully understood. 
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Secondary reference measurement procedure: A measurement procedure with high 
selectivity for the analyte and thereby being minimally influenced by any matrix 
components in the sample, in addition, the procedure should have high precision. 
Primary reference material: Is an ultra-pure material which contains the relevant 
analyte in a certified amount, any impurities are accounted for, and the material is stable 
and traceable. 
Secondary reference material: A reference material which often has a matrix close to 
that of clinical samples, or the material can be composed of a panel of clinical samples. 
Commutability: The processed sample tested has the same mathematical relationship 
between measurement procedures as is observed for representative authentic clinical 
samples.  
Matrix-related bias: Bias not normally seen in in authentic clinical samples but often 
in processed samples. 






The definitions are modified from VIM, Bolann, and Miller et al. (1-3). 
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1. Introduction 
In clinical chemistry, analyses of body fluids are performed to yield relevant, accurate, 
and precise information about the health status of the patient. The cornerstone of all 
laboratory medicine is that the in vivo processes in the human body can be understood 
by analyzing body fluids in vitro (4). The modern laboratory is a physical place fully 
equipped with complex measurement procedures (MPs) and staffed with professionally 
trained operators who analyze hundreds or even thousands of specimens daily (4). 
However, the history of laboratory testing started as isolated testing at the patient site 
with small and simple MPs, which were easy to use (4). Today near patient testing, or 
point-of-care (POC) testing, is again increasing as health services are becoming more 
patient centered, and it is now the fastest growing part of the laboratory testing market 
(5).  
External quality assurance (EQA) was launched over 70 years ago to address the 
observation that laboratory results for aliquots of the same sample showed different 
results when analyzed at different laboratories (6, 7). The results obtained from the 
EQA schemes were used to attain more uniform laboratory results among the 
laboratories. Today, EQA schemes are a crucial component of laboratories’ quality 
management systems, assessing both the analytical and the pre-and postanalytical 
performance of the laboratory. The EQA surveys are managed by distributing EQA 
samples with unknown concentrations to the participants. One of the most important 
properties of the EQA material is commutability, which affects both the design and the 
interpretation of the EQA results.  
The present thesis evaluates the commutability of EQA materials and the effect of 
participating in a quality improvement system for POC testing over time.  
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1.1 Point-of-care testing 
POC testing is a term used to describe laboratory tests carried out near the patient, 
rather than in the clinical laboratory setting. The aim of performing POC testing is to 
make laboratory test results available quickly and thereby expedite diagnosis and 
initiate proper treatment, with the intention of improving patient outcomes (8). The key 
features of POC testing include no sample preparation, no pipetting, reagents that are 
ready to use, no special medical technical background is needed to perform the tests, 
the instant availability of results, and the initiation of diagnosis and treatment without 
delay. POC testing is used in a variety of settings both within hospitals, such as in the 
intensive care unit, in the diabetic care ward, and in the operating and delivery rooms, 
as well as outside the hospital setting, such as the offices of general practitioners (GPs) 
and in home care for self-monitoring performed by the patients. There are currently 
POC tests for a broad range of clinical parameters, and new tests, such as the viral tests 
for influenza and Covid-19, are continuously being developed (9, 10). As no uniform 
term is agreed upon for this type of testing, POC testing is also termed “near patient 
testing”, “remote rapid testing”, “decentralized testing” or “bedside testing” (11).  
The MPs used for POC testing span from simple test strips to complex analytical 
systems. The MPs are, in general, more or less fully automated, and they tend to require 
very few steps from the point at which the sample is collected to the generation of the 
final test result. Different designs for POC MPs have entered the market, benchtop 
analyzers, which are complex analytical systems often used at GP offices, emergency 
departments, or in nursing homes, and hand-held MPs, which are mainly used at the 
bedside in hospitals or in the home environment. The MPs can provide either 
qualitative or quantitative test results. When using qualitative tests, the results are 
presented on an ordinal scale and on an interval or ratio scale when using quantitative 
tests. Hand-held POC testing is often performed using test strips, and the results can 
either be read directly or by using a simple MP. The analytical reaction for such MPs 
typically takes place inside the test strips, while the POC MP only generates a readable 
result. Benchtop analyzers are generally smaller versions of the analytical systems used 
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in central laboratories, in addition to being more compact, they are also faster and more 
user friendly (12).  
Since POC testing is performed outside central laboratories, these tests are more likely 
to be carried out by persons other than laboratory scientists, such as nurses, doctors, 
and other healthcare professionals, or sometimes, the patients themselves (13). 
However, there are concerns that POC testing performed by non-laboratory staff in a 
hectic clinical setting is especially prone to errors even though the POC MPs are easy 
to handle and vulnerable steps in the analyzing process, such as calibration and quality 
control, may have been automated (13).  
POC MPs in Europe are under governmental regulation by the European Union (EU) 
regulatory framework for in vitro diagnostic medical devices (IVDs). The current 
framework for POC MPs that are CE marked, the IVD Directive 98/79/EC (14), is 
currently being replaced by the new EU regulation, Regulation 2017/746, which will 
become effective from 2022. According to the IVD Directive 98/79/EC, all POC MPs 
are classified as IVDs, and they must fulfill the requirements regarding quality, safety, 
and performance, whether they are used in clinical laboratories by trained laboratory 
scientists, on the ward, or in the home environment by laypersons (15). IVDs are 
classified into four groups, “high-risk devices”, “risk devices”, “self-testing” (except 
self-testing for blood-glucose), and “others”, which have the lowest hazard potential. 
The different groups have different requirements stipulated by the Directive, which 
determine the design, production, and verification needed for the MPs. Most POC MPs 
are considered part of the “other” group, which does not include obligations from the 
manufacturer or a notified body to evaluate the MPs’ quality assurance system. The 
“self-testing” category has quite strict safety requirements, as the analyses are 
performed by laypersons outside the laboratories. In contrast, the POC MPs in the 
“other group” do not yet have any comparable safety demands (15). Drafts by 
international and European non-governmental standards organizations, such as the 
European Committee for Standardization and the International Organization for 
Standardization (ISO), can be adopted to technically specify the different requirements 
presented in the Directive. There are several standards that apply to POC MPs. 
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However, they are laid out for POC use in hospitals, by ambulance staff, or in the home 
environment by patients undertaking self-testing, whereas none of the standards 
address POC testing performed by non-laboratory staff in the community setting (16). 
Additionally, standards and guidelines can be acquired from other accredited 
organizations, such as the Clinical and Laboratory Standards Institute (CLSI), which 
drafts procedures intended for application globally using a recognized voluntary 
consensus process (17).  
The introduction of POC has the potential to innovate prevention, diagnosis, and 
monitoring of patients by shortening the turnaround time (TAT) of tests, i.e., the time 
taken from ordering of a test to when the result is received. The shortened TAT is due 
to eliminating the time required for both sample transport and sample preparation since 
the tests are performed at the patient site mainly using whole blood. The immediate 
diagnosis and shortened therapeutic process aim to reduce the time spent in hospitals, 
lower the cost of treatment, and improve the satisfaction of patients and staff (18). In 
developing countries, POC testing has the obvious potential to enable more patients to 
obtain access to laboratory tests in non-urban areas, where premises for running 
conventional laboratories are scarce. For example, studies performed in such settings 
have shown that introducing POC testing in the case of malaria testing has reduced the 
amount of anti-malaria drugs prescribed to persons with negative malaria test results 
(19). In the hospital setting, POC tests carried out in the emergency department, where 
a rapid diagnosis and patient triage are essential, should be advantageous. The 
usefulness depends, nevertheless, on the TAT of the central laboratory, the measurand, 
and whether the TAT is the time-limiting step in the particular setting (20). In the 
wards, a laboratory result from the hospital laboratory, available in a couple of hours, 
might be satisfactory to provide sufficient medical decision making. POC testing in the 
operating theatre may shorten the time in surgery or improve the success of operations, 
e.g., measuring the concentration of parathyroid hormone can facilitate 
parathyroidectomy (21). In hospital settings, the coordination of laboratory tests 
performed across different departments is especially important to prevent over-testing, 
which can increase costs. In outpatient settings, such as GP offices, a quick laboratory 
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result enables test results to be ready during a consultation. Consequently, the results 
can be discussed with the patient in the consultation, which has the potential to increase 
compliance, and enable the initiation of the relevant treatment without delay (22). 
Therefore, the wait for the patients is shortened, and they do not need to return for a 
follow-up consultation due to delayed laboratory results. There is, however, limited 
knowledge on whether shortening the TAT in GP offices actually improves clinical 
outcomes (23). Still, some studies have shown that using POC testing for patients with 
suspected urinary tract infections lowered antibiotic use, and testing patients with 
bacterial infections for C-reactive protein (CRP) resulted in earlier treatment (24, 25). 
Improved adherence to treatment can be an important advantage of POC testing and 
has been shown to be effective in cases such as self-testing in patients receiving 
anticoagulants (26). In many cases, choosing to implement POC testing can be as much 
an organizational choice as a medical one. For instance, in some areas in Norway, the 
distance to the nearest hospital laboratory is considerable, which makes POC testing 
useful, as it enables timely analysis of important analytes, such as CRP (27). In the 
Netherlands, POC was introduced because of financial cutbacks, which led to more 
care at the GP office level and downsizing of care offered in hospitals (27). The effect 
of using POC in primary health care can, however, be difficult to assess since many 
tests are linked to monitoring chronic diseases, and the impact of the testing might not 
be measurable before a substantial amount of time has passed.  
The use of POC testing is constantly growing, and POC MPs make up a significant 
share of the IVD market (28). As the number of POC MPs increases, so does the risk 
of reduced analytical quality of some MPs. In hospitals, systematic differences between 
the central laboratory and POC MPs can be recognized if the central laboratory 
supervises the POC MPs. In the outpatient setting, differences between POC MPs used 
in different locations can be identified when participating in EQA schemes.  
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1.2 Quality of laboratory testing  
1.2.1 The laboratory test process 
In 1981, Lundberg (29) introduced a new paradigm for the complete laboratory test 
process. In his approach, the testing process is organized in a loop, which begins with 
the physician deciding to request a laboratory test and ends with the physician deciding 
what measures to take after receiving the test result. Lundberg proposed splitting the 
test process into categories based on the laboratory testing order. The first category, the 
pre-preanalytical phase, involves the selection and ordering of laboratory tests 
according to the patient’s medical history and the clinical examination. The 
preanalytical phase comprises the identification and preparation of patients, collection 
and handling of samples, and possible transportation and storage of test materials. The 
analytical phase covers the sample analysis, and the postanalytical phase comprises the 
validation and reporting of the results. The post-postanalytical phase considers the 




Figure 1. The testing loop. The figure illustrates the clinical sample’s lifespan from a laboratory test is 
required until the test result is received. The clocks represent the time difference between POC and the 
central laboratory testing. The green colors represent the test phases and the text and arrows the testing 
process. The figure is modified from Lundberg’s figure “Brain to brain loop” (29). 
 
1.2.2 Laboratory errors 
Medical errors are preventable, unfavorable events associated with medical care (30). 
A recent publication estimated that such errors cause the death of about 5000 patients 
in the US each year (31). Laboratories are responsible for their share of medical errors, 
however, these errors are generally given less public attention (32). This may be 
because laboratories make relatively few mistakes overall compared to other medical 
fields, or it may be that laboratory errors are difficult for non-laboratory personnel to 
detect (32). Additionally, the laboratory testing process is complex with several steps 
involved, and the time from ordering a test to the interpretation of the results makes it 
hard to pinpoint the time and place of the error (32).  
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Lundberg’s categories can be used to help identify and group errors in the laboratory 
test process. The first and last phases of Lundberg’s testing loop are the pre-
preanalytical and post-postanalytical phases, both of which are located outside the 
laboratory. The remaining phases, the preanalytical, the analytical, and the 
postanalytical, are laboratory phases, and any errors here are therefore categorized as 
laboratory errors. Nevertheless, in many cases, only the analytical phase is fully 
controlled by the laboratory since the other phases often involve several different 
stakeholders (33). Studies have indicated that the pre- and postanalytical errors account 
for 60% and 20% of the laboratory test errors, respectively (33, 34). However, these 
errors are mainly diagnostic, including failure to use the indicated test, failure to follow 
up on the results, or diagnostic delays (35, 36). 
 
1.2.3 Errors in POC testing 
In the pre-preanalytical and post-postanalytical phases, errors are associated with 
ordering the most suitable laboratory tests and interpreting test results, respectively. 
In the preanalytical phase, errors can be caused by misidentification of patients or 
unsuitable patient preparation (for example, in terms of medication, diet, or time of 
sample collection). Errors can also be related to sample instability as a result of 
conditions during transport and storage. POC testing, however, eliminates the 
uncertainty due to stability since tests are performed at the patient site immediately 
after collection. The sample collection is, nevertheless, an important pre-analytical 
issue in POC testing. The most commonly used sample type in POC testing is capillary 
blood, although some MPs also analyze venous or arterial blood (37). Several 
challenges are related to capillary blood sampling. The capillary blood may have a 
variable composition depending on the blood circulation at the puncture site (37). There 
are also differences between capillary and venous blood that may influence some 
analyses, such as hematological and glucose tests. There is a correlation between the 
depth of the puncture and the amount of blood volume collected, and the correct 
technique, in addition to puncture aids, can therefore be important to obtain the correct 
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sample volume (37). Other important preanalytical factors are whether the first blood 
drop should be analyzed or discharged, which container should be used, and whether 
the container should be inverted after being filled with blood, which depends on the 
measurand (37). Processing the samples prior to analysis, for example, using 
centrifugation, is not an issue when performing capillary blood analysis, and 
consequently, associated preanalytical problems are eliminated. Inspection of samples 
in the central laboratory is essential to identify hemolytic, lipemic, and icteric samples, 
which may cause preanalytical errors. Hemolysis is one of the most common 
confounding factors in capillary blood sampling and can be triggered if the skin is 
squeezed during sample collection, therefore, it is essential to use the correct technique 
(37). Additional possible errors are mislabeling, interchanging, failure to deliver, or 
misplacement of patient samples (34). 
Analytical errors may involve difficulties regarding the MP used, for example, 
maintenance, the analytical principle, or issues with the reagent lot number (37). Errors 
in this phase may be difficult for physicians to recognize unless the results are 
incredibly divergent from what is expected, and the erroneous result is therefore likely 
to be used in the diagnosis and treatment of patients. Depending on the MPs used, some 
MPs have quality control processes integrated from the manufacturer to reduce errors 
and potential hazards. Such quality control processes can detect reuse of test strips, and 
additionally, some new glucose meters also test for strip damage, humidity, and other 
hazards that might influence the test results (37). There are concerns about the effect 
of using expired reagents on analytical quality in POC testing (38). Therefore, there are 
recommendations to check and discharge any reagents with expired dates, since the 
chemical coating of the test strips breaks down as the reagent ages, which in turn can 
lead to biased test results (39). Degeneration of test strips does not only happen after 
the expiration date, but it may also occur after a certain time interval after the containers 
containing the testing strips are opened (37). However, some POC MPs use barcodes 
that identify each bottle within a lot and start a countdown to the expiration date when 
a bottle is first scanned (37). Similarly, some POC MPs have calibration factors that 
have been integrated into the product by the manufacturer, so the POC MP initiates an 
automatic calibration as the test strip or cartilage is scanned. There are some MPs, for 
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example, glucometers, that possess lockout functions, which prevent MPs from being 
used in cases where quality control testing has not been documented (37). The lockout 
function can also be used to ensure that only qualified operators with valid training are 
handling the POC MPs by requiring that the operator’s ID is scanned before analysis 
(37). In cases where there is an electronic transfer of patients’ results from POC MP to 
medical records, the entry of incorrect patient IDs can impede the transfer of test 
results. Since the test results are available on the POC MP, treatment can be initiated 
without the results being documented in the patients’ records, and vice versa. An 
incorrect patient ID entered into a POC MP can result in test results being transferred 
to the wrong patient record. Positive patient IDs, where a second identifier is 
mandatory, are integrated into many new POC MPs and ensure that patients’ 
information is correct before testing is allowed (37).  
Errors in the postanalytical phase may not be specific to POC testing but are relevant 
to obtaining high-quality test results in POC testing. Errors may occur in the validation 
of test results, especially in situations where the tests are performed under high pressure 
to fulfill short turnaround times. There is also the possibility of incorrect or delayed 
reporting of results, erroneous entry of test results into mismatched patient records, or 
a completely missed notification of test results (34). Errors in the postanalytical phase 
are often related to the organizational settings, for example, how well the POC MPs, 
laboratories, and wards are linked. Additionally, the number of controls in POC testing 
is often limited compared to the central laboratories, and as a result, there is an 
increased risk that errors can impact patients (40).  
 
1.3 Analytical quality 
All laboratory analyses are subject to uncertainty in the analytical phase, and regardless 
of how carefully the analysis is performed, every single measurement differs slightly. 
Analytical variation can either be random or systematic and will be discussed further 
below. Additionally, test results are influenced by uncertainty due to biological 
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variation. Biological variation is a natural variation that occurs either within a person 
(known as intra-individual biological variation, which is the biological variation around 
a homeostatic set-point) or between persons (called inter-individual biological 
variation, which is the variation between individuals with different homeostatic set-
points) (41). Typically, analytical variation should not exceed more than half of the 
intraindividual biological variation. This is because when the analytical variation 
exceeds more than half the intraindividual biological variation, it constitutes less than 
12% of the total variation (analytical and intraindividual biological variation). It is, 
however, not always possible to achieve an analytical variation of less than 12%, and 
the expected analytical variation for different analyses is summarized in different 
manuals (42). The biological variation for different analyses can be obtained from the 
European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 
Biological Variation Database (43).  
 
Figure 2. Variation in a laboratory test result. The figure illustrates different forms of variations 
influencing the laboratory test result.  
 
Random errors are part of analytical variation, and they limit the precision of the 
performance of the MPs. The precision can be quantitatively expressed as imprecision, 
also referred to as analytical variation. Imprecision can be stated numerically as the 
standard deviation (SD) or the coefficient of variation (CV), assuming the MP is 
performing under given specifications. These specific conditions (listed with an 
Variation in a laboratory test result
Pre-preanalytical variation Preanalytical variation
Analytical variation Biological variation
Postanalytical variation Post-postanalytical variation
Laboratory test result
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increasing degree of variability) are repeatability, intermediate precision, and 
reproducibility (1). These conditions may also be divided into imprecision within one 
laboratory (comprising repeatability and intermediate precision) and imprecision 
between laboratories (reproducibility).  
The calculated SDs and CVs become more reliable as more data are included, however, 
there is always a level of uncertainty associated with calculations, characterized as 
confidence intervals (CI). The CI denotes the uncertainty of a performed measurement, 
and the prediction interval (PI) denotes the limits where a future value from the same 
population will fall with a given probability. The limits of the PI are wider than the 
corresponding CI, but the intervals approach each other as n increases (2). When 
repeated measurements are performed on the same aliquot, the dispersion of the results 
will, in general, follow a normal distribution scattered around the mean. The expected 
imprecision of the measurement results gives a statistical probability of 68.3% of the 
results falling within 1 SD, 95.4% within 2 SD, and 99.7% within 3 SD of the mean 
(3). 
In contrast to random error, which may have both a positive and a negative direction 
from the mean, systematic error (bias) is caused by the deviation of all the measurement 
results in one direction. A difference between the observed mean and the expected 
result is then introduced. Bias can be expressed as either a percentage or an absolute 
value. Calculating bias is, however, often more challenging than calculating 
imprecision, as the true value may not be known. Ideally, the measurement results 
should be compared to a traceable reference MP to assess whether systematic bias is 
present. Otherwise, an indication of the MP’s performance can also be obtained 
through participation in EQA or by the participants’ internal quality control (IQC), 
demonstrating a shift of the results in one direction. Trueness is inversely related to 
bias and characterizes how well an MP is calibrated to a traceable reference system.  
An MP’s imprecision and bias make up the total error (TE) of a measurement result. 
The TE gives an estimate of the limits of an interval, whereby the unknown “true” 
value can be found with a defined probability (usually 95%). The TE is useful both for 
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evaluating a laboratory’s assay quality and for setting quality goals for different clinical 
tests (3). Different approaches have been suggested for calculating TE, and the CLSI’s 
recommendations are elaborated in the EP21A guidelines (44). The TE is expressed in 
qualitative terms as accuracy.  
After calculating the TE limits, the allowable TE (TEa) for a particular analysis is 
determined. TEa refers to the amount of error that is allowed for the particular analysis. 
The TE must not exceed the limits of TEa to ensure that the MPs are of adequate 
analytical quality (2).  
An objective criterion for determining TEa, and thereby whether the analytical quality 
is acceptable, is essential. TEa can be estimated by establishing analytical performance 
specifications (APS) using three different models arranged hierarchically (45, 46). In 
the first model, the APS are based on the effect of analytical performance on clinical 
outcomes. This effect can be determined using direct outcome studies, ideally using 
randomized controlled trials, which investigate how a test’s analytical performance 
impacts clinical outcomes (Model 1a). A more pragmatic alternative is utilizing 
indirect outcome studies, for example, simulation or decision analysis, where the 
influence of a test’s analytical performance on clinical classifications or decisions (and 
consequently the probability of clinical outcomes) is investigated (Model 1b). This 
approach is often used when establishing APS in laboratory practical guidelines (47, 
48). Although Model 1 is preferred, it can only be used in situations where the links 
between the test, clinical decision making, and the clinical outcome are straightforward 
and measurable (49). The second model defines APS based on biological variation. 
The approach attempts to minimize the ratio of the analytical variation to the biological 
variation, which will identify MP performance relating to medical requirements. The 
data for this approach are acquired from studies of biological variation. In the third 
model, the APS are based on the “state of the art” in the field. This model is 
benchmarked using the highest level of analytical performance technically achievable, 
or, in other words, the analytical performance obtained by a particular percentage of 
laboratories. There is no official consensus on how to determine specifications using 
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this approach, but data derived from EQA schemes or empirical data have been 
suggested (2).  
 
1.4 Analytical quality control 
Several quality control systems can be implemented to detect potential errors. In 2000, 
the Swiss cheese model of errors was introduced, which uses the metaphor of stacked 
slices of cheese to describe the system. In this metaphor, the defense layers of the 
system are like slices of cheese, and the weaknesses in the system are represented by 
the holes (50). Although no system is entirely safe, since there are holes in each defense 
layer that allow errors to pass, multiple layers will lead to most errors being caught.  
 
 
Figure 3. The swiss cheese model. The figure illustrates that several defense layers lie between the 
hazards and errors, but flaws in each layer may cause errors to happen. The figure is modified from J. 
Reason figure “Swiss cheese model” (50).    
A quality management system is constructed to reduce laboratory errors and ensure 
that the test results are suitable for supporting decisions about patient care. The quality 


















control of the analytical process consists of IQC and EQA, and the results obtained 
from patient sample testing can also be used to monitor performance. 
 
1.4.1 Internal quality control 
IQC is continuous, day-to-day surveillance of the stability of the laboratory’s MPs and 
working routines. This evaluation aims to identify, decrease, and correct any 
insufficiencies in the laboratory’s analytical process and to verify that the MPs meet 
the predetermined quality specification at the time of the analysis. This fundamental 
characteristic of IQC, coupled with an evaluation of analytical performance, makes it 
possible to intervene without delay if any insufficiency is detected (3). 
In the central laboratory, the IQC material of at least two different concentrations is 
measured along with patient samples (51). The target values and the SD for the IQC 
materials are calculated, and statistical control rules are established based on the TEa 
and APS for the MPs. The control rules are statistically set up to alert the user if the 
IQC’s TE exceeds the TEa, which indicates that some patient samples analyzed in the 
run might have a TE that exceeds TEa, and there is a risk of erroneous patient results 
(3).  
IQC in POC testing may present further challenges. The POC MPs are often operated 
by persons who do not hold a laboratory degree and need to be convinced that IQC is 
important to detect errors. Unfortunately, the evidence that measuring IQC improves 
POC quality is limited (52, 53). The MPs utilize different technologies that require 
different levels of IQC. MPs using technology similar to the wet chemistry in central 
laboratories, for example, require more frequent IQC than cartilage- or strip-based 
MPs, where the chemical reaction takes place inside the cartilage/strips. Additionally, 
some MPs have “built-in” controls that can either be placed in the MP itself to assess 
whether the electronics of the MP are working properly, or they can be placed in the 
cartridges or strips. However, it has been argued that relying only on such control 
systems is inadequate, and IQC is recommended (54). 
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1.4.2 External quality assurance 
EQA entails continuous monitoring of the analytical quality of laboratory analysis, as 
well as confirmation that the test results conform to the expectations required for 
patient care (55). Additionally, several laboratories perform EQA as part of a 
framework that is required when seeking accreditation or to assess pre- and 
postanalytical efforts (56). 
ISO 17048 provides information on how EQA programs should be organized and 
managed by the laboratories (57). Generally, the EQA surveys are performed by an 
external organization circulating sets of quality control samples, the EQA material, to 
its participants. The EQA material simulates clinical samples with unknown 
concentrations and should be analyzed in the same manner as patient samples. The 
results of the analyzed EQA material are reported to the EQA organization for 
evaluation. The EQA organizer assigns target values for the EQA material, and the 
participants’ analytical quality is evaluated by assessing the difference between the 
participants’ results and the target values. A report is prepared that includes the 
participants’ results, the MP used, the expected target value, and an evaluation of the 
participants’ analytical quality. The EQA organizer also offers group data analysis at a 
national level, where the results from different participants using the same MPs for the 
same measurand are compared. Verification of whether the participants’ performance 
and MPs are in conformance with other participants is then possible (55). 
The nature of the EQA material is highly important, since it affects how the results 
obtained from the EQA scheme can be interpreted (58). Information on whether the 
EQA material is commutable or likely to be commutable, if the material is known not 
to be commutable, if there are any specific limitations in the commutability of the 
material, or if the commutability has not yet been assessed, should be specified for each 
survey (58). When distributing a commutable EQA material, the samples mimic real 
clinical patient samples as closely as possible, and the participants’ results reflect those 
expected from measuring real patient samples (55). However, providing commutable 
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EQA material for all measurands and all MPs is challenging, and in such cases, 
noncommutable EQA material is used in the EQA programs. Noncommutable EQA 
materials do not behave like clinical patient samples and therefore only allow for 
evaluation of the participants’ performance in relation to the MP used (55). The EQA 
material and commutability are discussed in detail later.  
A target value and its associated uncertainty must be established by the EQA organizer 
to enable interpretation of the EQA results. Ideally, the target value is obtained from a 
reference MP or a comparative MP with high specificity, traceable to a reference MP 
(55). The target value can also be established by value transfer using a commutable 
certified reference material (CRM) (59, 60). Preferably, the traceability should be 
determined by reference MPs and CRMs listed in the database of the Joint Committee 
for Traceability in Laboratory Medicine (61). There is also an option for weighted 
values in cases where the purity of the material, the accuracy of the MP, and the 
similarity between the purified material and its endogenous form in human samples are 
verified (55). Establishing a target value using a reference system is most beneficial in 
cases where the EQA material is commutable. When the commutability of the material 
is not known, it is not possible to know whether deviations from the target value are 
due to a calibration bias or a matrix-related bias. If a reference system is not in place, 
the mean or median of all participant results can be used as a target after excluding 
outliers, providing that the EQA material is commutable, and the same result is 
expected for all MPs used. In cases where the commutability of the EQA material is 
not established, it is common to separate the participant results into “peer groups” of 
MPs with similar technology, which are assumed to obtain equivalent results when 
measuring the EQA material after excluding outliers (3). Usually, the peer group 
consists of MPs from the same manufacturer. How the peer group target values are 
calculated is important, attention must be paid to how outliers are treated, and the 
amount of uncertainty associated with the target value, especially in situations where 
the data are limited. An all-participant mean/median can be used in situations where all 
MPs have a similar matrix-related bias or are equal in size, as there otherwise is a risk 
of the target mainly reflecting the largest MP group (55). 
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The difference between the EQA results and the target value is evaluated to assess 
whether the participants’ analytical quality is adequate. The EQA organizer creates the 
APS for the measurands involved to determine whether the deviation from the target 
value is acceptable. The APS are often denoted as units or percentages based on the 
target value, determining the lower and upper acceptance limits (58). However, the 
criteria for evaluating adequate performance differ among EQA providers (62). Some 
countries have regulations defining the criteria that the EQA organization is required 
to follow, while other EQA providers assign evaluation criteria (the APS) themselves 
(63). Some EQA providers use statistical limits, for example, z-scores, where there is 
an assumption that the EQA results of the MPs are acceptable if they are in concordance 
with others using similar MPs (3). Other EQA organizers establish their APS based on 
clinical criteria or biological variation (64, 65). Consequently, there are large 
differences in the APS for the same measurands used by different EQA organizers due 
to, for example, differences in the data on which the APS are founded or the different 
criteria used in establishing the APS (58). There are, nevertheless, published 
recommendations on different models to use when establishing APS, along with 
guidance on how to achieve harmonization among different APS for the same 
measurands (58, 66). The APS used for EQA materials often have wider limits than the 
corresponding TE for clinical patient samples, as both the variability for the particular 
measurand and the error components unique for EQA materials must be taken into 
account. Examples of such unique error components include between laboratory 
variation in the calibration of MPs, matrix-related bias due to differences in the lots in 
peer groups, the uncertainty of the assigned target value, as well as stability and 
homogeneity issues in the EQA material. When the APS are established for a single 
measurement, the limits are wider since TE is assessed. When multiple EQA results 
have been retrieved from the EQA material, bias and imprecision can be evaluated 
separately, and the APS limits can be narrower (58). In cases where the EQA material 
is noncommutable and the target value is assigned by calculating the peer group’s 
mean/median for similar MPs, the APS should consequently be stricter, as the variation 
in the results is limited to the particular MP group (58). 
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Interpreting EQA results when the EQA material is commutable has the advantage that 
the relationship between the EQA results corresponds to the relationship observed for 
clinical samples (3). The participants can then determine the accuracy of their clinical 
patient results by comparing them to the EQA results, with a target value preferably 
established by a reference MP. The results should then, in theory, be the same for all 
MPs, reagent lots, and routine MP calibrators, and the variation seen in the results 
reflects real differences between the MPs, lots, or calibrators (55). Consequently, the 
results from EQAs can be used to assess the harmonization status of patient results 
between different MPs, and the outcome of calibration standardization or 
harmonization among participants can be assessed (67-69). MPs that do not perform as 
expected can be identified, and the calibration can be corrected by the manufacturer. 
The EQA results can also be useful for detecting measurands that need improvement 
and, hence, enable the initiation of adjustments to promote reaching clinical 
requirements (70, 71). 
Interpreting EQA results when the EQA material has unknown commutability has 
limitations because the matrix in noncommutable EQA materials can induce bias 
between MPs, which is not seen when measuring clinical patient samples (67, 72-74). 
Direct verification of the accuracy of clinical patient results based on the EQA results 
is, therefore, not possible since actual differences cannot be separated from any matrix-
related bias. Still, quality can be assessed, and participant performance can be 
evaluated. It is also possible to verify that the participants are using the MPs in 
accordance with the manufacturer’s instructions and the other participants in the same 
peer group, for example, using similar MPs (55).  
EQA programs can be assigned to one of six categories based on their ability to 
evaluate the participants’ performance (Table 1) (3). The EQA programs’ ability to 
evaluate performance depends on the EQA materials’ commutability, the process used 
to establish the target value, and whether the participants analyze the EQA material in 
replicate (55). Category 1 is preferred, as it includes commutable EQA material and 
target values that are traceable to a reference MP or CRM, which allows for assessing 
both participant performance and the MPs for calibration traceability, reproducibility, 
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repeatability, and harmonization among participants and MPs. In category 2, the EQA 
material is analyzed in singlicate, and consequently, the within-laboratory 
reproducibility cannot be assessed, otherwise, the category has the same qualities as 
category 1. Categories 3 and 4 include EQA programs using commutable EQA 
material, but there is no reference measurement system in place for establishing the 
target value, which limits the ability of the evaluation to assess the uniformity, or 
harmonization, among participants and MPs. EQA programs in categories 5 and 6 use 
noncommutable EQA materials, and the evaluation is limited to a peer-group 




Table 1. EQA scheme design. Evaluation capability of different categories of EQA schemes. The table 
is modified from Miller et al. (3). 


























































1 Yes Yes Yes X X X X X X X 
2 Yes Yes No X X X  X X X 
3 Yes No Yes  X X X X  X 
4 Yes No No  X X  X  X 
5 No No Yes   X X X   
6 No No No   X  X   
 
 
1.4.3 EQA in primary care in Norway 
EQA in Norway is provided by the Norwegian Organization for Quality Improvement 
of Laboratory Examinations (Noklus). More than 3600 participants are voluntarily 
engaged, and GP offices and nursing homes account for the majority of participants 
(over 99% and 96% of all GP offices and nursing homes are enrolled, respectively) 
(75). Currently, Noklus distributes EQA schemes for 21 analyses, each of which is 
circulated between one and four times annually, engaging between 80 and 2900 
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participants (75). Noklus is one of the few organizations globally in possession of EQA 
data covering nearly 30 years of primary health care (76).  
Noklus provides a quality management system covering the total testing process, 
complying with the requirements of the NS-EN ISO 9001:2015 and the NS-EN 
ISO/IEC 17043:2012 standards (57, 77). Figure 4 illustrates how Noklus works with 
the participants to improve the quality management system and, in the end, reach the 
common goal of providing safe patient care. Initially, the process starts with Noklus 
producing “in-house” EQA materials resembling real patient samples, which are 
distributed to the participants by mail. The participants analyze the EQA material in 
duplicate on two different days. Analytical results, information on the MP used, and 
additional characteristics of the participants are reported back to Noklus. At Noklus a 
target value is assigned for some measurands by a reference MP or value transfer using 
a commutable CRM, and for others using a peer group median after excluding outliers. 
When using a target value from a reference MP, Noklus obtains the value from an 
external body. When using CRMs, the target value is obtained by measuring the EQA 
material and the CRMs using an MP with excellent precision and then calculating an 
inverse regression line against which the EQA material can be assessed. In cases where 
a peer group target value is used, the target value is calculated according to ISO 
13528:2015 (78). At least eight participants are needed in a peer group for the estimated 
target value to be statistically robust. An interval of uncertainty around the target value 
is established both to address the uncertainty of the defined target value and to ensure 
that the APS are relatively wider at lower concentrations of the measurand. The target 
value and its uncertainty are communicated to the participants.  
Noklus uses APS, which are defined using a combination of fixed percentage limits, 
intraindividual biological variation for the particular measurand, state-of-the-art and 
expert opinions to assess the participants’ analytical quality (58). The participants 
receive an evaluation of the trueness and precision of their duplicate results graded as 
“very good”, “acceptable”, or “poor” based on the APS. When the data analysis is 
performed and the test results are interpreted, Noklus prepares an individual feedback 
report for each participant.  
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Through the EQA, the participants can communicate any difficulties they experience 
when performing the EQA back to Noklus. Noklus supports the participants in the 
process by answering questions and providing advice to enable them to achieve the 
best laboratory quality possible. Noklus also provides three preanalytical 
questionnaires and one postanalytical questionnaire yearly to the participants to ensure 
that the total testing process is covered.  
 
 
Figure 4. Noklus improvement process. An illustration of how Noklus works to continuously improve 
quality. Noklus and the participants have a common goal of providing safe patient care. The green area 
illustrates the contribution from Noklus, the blue area illustrates the contribution from the participants 
and the grey arrow illustrates the interaction between the two.  
 
1.5 Measurement procedure performance 
Obtaining clinical test results that are comparable irrespective of the MP used is a high 
priority for the utility of laboratory information. While standardization refers to MP 











































ideally to the Système Internationale (SI), harmonization denotes that the MP results 
must be equivalent without emphasizing the process of achieving such results (3). 
Harmonization and standardization aim to provide consistent and comparable 
laboratory results regardless of the MP used and the time and place of the analysis (79). 
They allow for common reference intervals and the use of clinical practice guidelines 
with fixed decision limits. This also enables laboratory data to be gathered from various 
sources and thereby helps to identify public health issues, monitor health programs, 
and facilitate comparisons of data derived from different studies (80). If the EQA 
material is commutable, standardization allows for common target values for EQA 
organizations, which can be used to objectively evaluate the performance of IVD MPs 
and to provide the participating laboratories with an accuracy-based common grading 
of their performance (81).  
The entire test process, i.e., the preanalytical, analytical, and postanalytical aspects, 
must be taken into consideration to achieve harmonization. 
Preanalytical aspects include having a standardized terminology to make sure the 
correct test is ordered, assuring that the patients are following the rules of preparation, 
and that the specimen collection process is performed without errors. 
Postanalytical aspects involve using standardized terminology to make sure the test 
results are correctly communicated, ensuring that the reporting units are identical to 
avoid any misinterpretation, and providing uniform reference intervals and decision 
values to prevent different clinical interpretations of the same laboratory results.  
The pre- and postanalytical aspects of harmonization will not be further discussed in 
this thesis.  
Analytical aspects to consider are the measurand, traceability, and commutability. 
The measurand is defined as the quantity intended to be measured (1). Inadequate 
definition of the analyte can lead to different entities being measured by different MPs. 
Human chorionic gonadotropin, for example, is known to have several isoforms 
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depending on the clinical setting, for example, tumors and pregnancy (82). Another 
prerequisite is the analytical specificity of the MPs. If the MPs are influenced by other 
substances in the sample, different results may be obtained from the same sample (83).  
 
 
Figure 5. Traceability chain. An illustration of the traceability chain starting with the SI-unit at the top 
of the hierarchy and ending with the patient result. Traceability is achieved by value assignment 
through an unbroken chain of calibrators. Since all calibrations have stated uncertainties, the amount 
increases the further down we are in the traceability chain. The figure is modified from ISO 17511:2020 
(79).  
Traceability aims to link clinical results from routine MPs to higher-order reference 
standards (79). This is achieved by establishing a hierarchical reference measurement 
system consisting of reference materials and reference MPs, where each level is joined 
through an unbroken chain of calibrators.  
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The reference MPs and reference materials are the key components of the traceability 
chain. The SI is at the highest hierarchical level of the chain, followed by a primary 
reference material and a primary MP. However, in cases where this is not possible, it 
may be possible to establish traceability to the WHO International Biological 
Preparations. This is an “artefact standard” reporting concentrations using the 
International System of Units and is used, for example, in assessing total Hb (80). 
Ideally, a primary MP is used in the value assignment of the reference materials, 
however, (for various reasons) not all analytes are compliant with the primary MPs 
available. The primary reference material (often several concentrations) is used as a 
calibrator for a secondary reference MP. The secondary reference material is used by 
the manufacturers to calibrate the internal MP they have selected to assign values to 
their working calibrator, and this is also known as the master lot of the calibrator. A 
master lot is used by the manufacturer to calibrate the manufacturer’s standing 
procedure, which is used to assign values to product calibrators. The master lot can be 
used over several years to assure traceability of different lots of product calibrators, 
which in turn are used to calibrate the routine MPs in clinical laboratories used to 
measure patient samples. 
Each step in the traceability chain is associated with some degree of uncertainty, which, 
in combination, represents the total uncertainty of the final patient result. Approaches 
to reduce imprecision in each calibration are therefore essential, in addition to adopting 
the minimum number of traceability steps necessary (84).  
Traceability of calibrators and control materials to reference materials and/or reference 
MPs is required according to the EU Directive on IVD Medical Devices. In a database 
held by Bureau International des Poids et Mesures (JCTLM), information can be 
obtained for all certified reference materials, reference MPs, and reference laboratories 
complying with ISO standard 17511 for reference systems for measurands (61, 79).  
There are several measurands for which no higher-order reference materials or MPs 
are available. In these cases, traceability ends with the manufacturer’s master lot, and 
consequently, the results from patient samples will differ depending on the MP used at 
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the laboratories. However, there are ongoing discussions about making calibrations 
traceable to harmonization protocols. These protocols are based on international 
consensus and aim to obtain uniform measurements for MPs that lack either a reference 
material or a reference MP (85).  
Commutability of the reference materials used as calibrators in the traceability chain is 
essential to ensure that they are fit for use. The noncommutability of reference materials 
used as calibrators in the traceability chain is a contributor leading to a lack of 
agreement among different MPs (86). Commutability is especially important for 
secondary reference materials that are used as common calibrators and may not be 
encountered until after the production and certification process, since the reference 
MPs involved are relatively matrix independent (84, 87). Nevertheless, commutability 
can be a challenge due to alternations in the matrix during the preparation of the 
reference material. Manufacturers often provide target values for calibrators intended 
for specific MPs, which can be used to correct for any noncommutability and make 
patient sample results from this specific MP traceable. However, the calibrators will 
not be commutable when used with different MPs.  
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Figure 6. CRP. Human C-reactive protein by Ramadan, M.A., Shrive, A.K., Holden, D., Myles, D.A., 
Volanakis, J.E., DeLucas, L.J., Greenhough, T.J.; User: Astrojan 
(https://commons.wikimedia.org/wiki/File:1lj7.jpg). Licenced under Creative Commons BY 3.0. 
 
There has been a great effort since the late 1960s to standardize serum protein 
measurements to reduce the poor between-laboratory agreement seen for serum protein 
measurements results (88). The introduction of the ERM-DA470 (CRM-470) has 
especially resulted in improved harmonization of the serum protein measurement 
results in general (89, 90). For CRP, this standardization has permitted the use of 
common reference intervals and thereby allowed for patient results to be compared 
over time between different laboratories.  
Standardization of serum proteins is challenging due to genetic variability, post-
translational alternations, ligand-binding, proteolysis, and the fact that many proteins 
can differ substantially in their concentration in serum. Native CRP is a cyclic 
pentameric protein with an annular configuration. The molecule consists of five non-
glycosylated subunits, each made up of 206 amino acids (91). The subunits, known as 
protomers, contain a pocket with two bound calcium ions. The calcium ions are crucial 
for all ligand binding of CRP and to enable the molecule to retain its pentamer structure 
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(92). There have been indications that the CRP molecule may show heterogeneity in 
vivo, nevertheless, no polymorphism has yet been confirmed (92).  
Currently, there is no established reference MP for analyzing CRP stated by JCTLM, 
and the standardization process therefore relies on the availability of reference 
materials (61, 93). The CRP MPs are traceable to the certified reference materials 
ERM-DA474/IFCC (CRP in processed human serum) and ERM-DA472, which are 
traceable to SI via ERM-DA470/IFCC and CRP WHO 85/506 (94, 95). The reference 
material for CRP is a separately produced liquid frozen material, and CRP is not part 
of the common reference material for serum proteins, ERM-DA470k/IFCC. The ERM-
DA470k/IFCC was produced to fully replace the common reference material for serum 
proteins DA470/IFCC. However, the newly produced reference material for serum 
proteins was shown to be unsuitable for CRP. The lyophilization process that takes 
place to create the material may have altered the pentameric structure of CRP, thereby 
increasing the amount of monomeric CRP. Since monomeric CRP in vivo is 
predominantly membrane-bound and is, as a result, not measured by immunoassay 
methods, a liquid frozen nonlyophilized reference material was prepared instead (93).  
Commutability of the ERM/DA/IFCC material has been evaluated for several batches 
using different buffers, antibodies, and reagents. The CRM was assessed as 
commutable for most immunoassays, however, if the CRM is intended to be used for 






Figure 7. Glucose. “Druesukker” by Johannes Botne (https://snl.no/druesukker). Licensed under 
Creative Commons BY SA 3.0. 
 
The measurement of glucose is used in a variety of clinical settings, with a range of 
different sample types and measuring techniques being used. Harmonization of glucose 
measurement results has therefore been challenging, but increased attention from, for 
example, the International Federation of Clinical Chemistry (IFCC) Scientific 
Division’s Working Group on Selective Electrodes and Point of Care Testing (IFCC-
SD-WG-SEPOCT) has been conducive. Both glucose measured in serum and whole 
blood have adequate harmonization/standardization according to the International 
Consortium for Harmonization of Clinical Laboratory Results (85).  
Glucose is a small measurand that is well-characterized in both chemical and physical 
terms (80). The molecule is a hexose monosaccharide existing in two different isomers, 
D-glucose and L-glucose. The two isomers mirror each other but are otherwise 
structurally identical. D-glucose is biologically active and occurs in two forms, -D-
glucose and -D-glucose, which make up 36% and 64% of D-glucose at equilibrium, 
respectively (96).  
In whole blood, glucose is distributed between erythrocytes and plasma, and although 
the molality of glucose is equal throughout the sample, the concentration of glucose is 
higher in plasma compared to the intracellular glucose concentration. Samples can be 
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whole blood (venous, arterial, or capillary), plasma, or serum samples from 
centrifugated venous whole blood. The glucose measurements are performed using 
various types of MPs with different principles for detecting glucose. The units for 
reporting glucose measurement may also differ depending on the laboratory, whereas 
many now prefer mmol/L, some still report glucose values in mg/L. To harmonize 
glucose measurement results, the IFCC-SD-WG-SEPOCT recommends reporting 
glucose concentrations in plasma irrespective of sample type or MP used, using the 
unit mmol/L and applying a conversion factor of 1.11 to make whole blood and plasma 
results equivalent (97). Another variable to take into consideration when analyzing 
hemolyzed whole blood samples is hematocrit. A patient with low hematocrit (< 30%) 
can have falsely increased glucose results, while a patient with high hematocrit (> 60%) 
can have falsely reduced glucose results. The degree to which hematocrit affects the 
measurement results depends on the MP used and must be taken into consideration.  
Despite the challenges regarding the harmonization of glucose measurements, the 
measurand has full traceability to a complete reference system. The SI unit of glucose 
(mmol per liter) is included in the primary reference material, NIST SRM 917b 
(crystalline glucose). This material is composed of chemically purified glucose, and 
the material is used to prepare calibrators used for isotope dilution mass spectrometry 
(ID GC-MS), which is the established secondary reference MP for glucose (61, 98, 99). 
ID GC-MS combines mass spectrometry with isotope dilution and is currently the most 
accurate known method for analyzing glucose. The ID GC-MS reference method is 
suitable for the analysis of glucose in whole blood (Deutsche Vereinte Gesellschaft für 
Klinische Chemie und Laboratoriumsmedizin, Germany) and for analysis in serum 
(Gent University, Belgium) (61). ID GC-MS is used to measure glucose concentration 
in the CRM SMR 965b (glucose in frozen human serum) (61).  
Commutability of the secondary reference material NIST SMR 965b has not yet been 
evaluated. The certificate of analysis states that although the National Institute of 
Standards & Technology (NIST) is unaware of any problems with commutability, the 





Figure 8. Hb. Hemoglobin by OpenStax (https://openstax.org/books/anatomy-and-
physiology/pages/1-introduction). Licenced under Creative Commons BY 4.0. 
 
The standardization of hemoglobin (Hb) began in the early 1960s after widely different 
results for Hb were obtained using a variety of different MPs (101). A consensus on 
using photometric determination after the conversion of Hb into cyanmethemoglobin 
(HiCN) was established by the International Council for Standardization in 
Hematology (ICSH) (101). HiCN is the current reference MP for Hb measurements 
stated by JCTLM, and the harmonization status of Hb is referred to as adequate (61, 
85). 
The measurand Hb is structurally and physically well-defined. The molecule is made 
up of a protein part, globin, surrounded by four hem molecules forming a tetramer. The 
globin consists of two linked pairs of polypeptide chains. Approximately 97% of the 
total Hb in adults is HbA, which has 2 - and 2 -chains, the remaining Hb are HbA2 
composed of 2 - and 2 -chains and some fetal Hb, HbF, consisting of 2 - and 2 -
chains. Each of the polypeptide chains is linked to hemoproteins, which are circular 
porphyrins s (a class of water-soluble, nitrogenous pigments) with an iron atom (Fe2+) 
attached (102). There are several different Hb derivates in vivo, with different 
absorption spectra present in the blood. As a result, prior to spectrophotometric 
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analysis, whole blood samples must be diluted to obtain a homogenous solution. The 
transformation of Hb into hemiglobincyanide before analysis is at present considered 
to be the most reliable procedure (103).  
Hb measurements are not traceable to SI but are traceable to a conventional reference 
procedure and a conventional reference material defined through consensus by the 
ICSH (80). The reference MP stated by JCTLM is HiCN, which measures the color 
product of hemiglobincyanide, facilitating a spectrophotometric method (61). The 
method is accurate, reproducible, and thoroughly investigated, and the reagents are 
inexpensive. HiCN is calibrated using BCR-522 bovine blood lysate 
(hemiglobincyanide) from the Community Bureau of Reference (104). This reference 
material is intended to calibrate the HiCN to validate the secondary reference materials. 
At Noklus, participants have their Hb EQA results assessed against a target value 
obtained from a HiCN method at the Odense University Hospital (Odense, Denmark). 
 
1.6 The EQA material 
Since the EQA material is the key component in the EQA scheme, it should ideally 
possess characteristics enabling the assessment of individual MPs and their accuracy, 
precision, and calibration traceability, as well as a collective evaluation of the 
laboratories, assessing their reproducibility, standardization, and overall harmonization 
(3). The EQA material must possess a range of qualities to be able to fulfill these 
requirements. First, the appropriate sample type (e.g., whole blood, serum, or urine) 
must be available in a sufficient amount, the material should be at a clinically relevant 
level, and should cover clinical decision points of the measurand in both normal and 
pathological concentrations. The material must be practical to handle, free of any 
pathogens (unless they are the purpose of the EQA scheme) and should be available at 
a reasonable price. It should be homogenous across aliquots and stable for both short 
and long times under the conditions in which the material will be transported and 
stored. Finally, the EQA material must behave in the same way in the routine MPs as 
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the clinical samples they mimic, hence, they must be commutable. Commutability 
between the EQA material and clinical samples is essential and affects both the EQA 
scheme design and the ability to interpret the results obtained from the participants 
(55). This will be discussed in more detail below.  
The EQA materials distributed by the EQA organizer are intended to be used as 
surrogates for authentic clinical samples usually measured at the laboratory. They must 
therefore mimic clinical samples as closely as possible, and the EQA materials should 
(ideally) be directly entered into the laboratory workflow without any special handling.  
 
1.6.1 The EQA material for POC CRP, glucose, and Hb 
POC testing is designed for rapid analysis. Using whole blood, which is easy to obtain 
from a capillary finger prick, does not require extensive processing like centrifugation 
and makes the sample type ideal for many laboratories in primary health care. Another 
positive feature of using whole blood capillary samples is that the total sample volume 
needed for testing is minimal. The POC MPs for CRP, glucose, and Hb are usually 
calibrated to measure whole blood. 
Therefore, distributing whole blood EQA materials to the participating laboratories is 
preferable for mimicking real patient samples as closely as possible. The whole blood 
material can be prepared from either single donors or pooled samples. The number of 
aliquots required frequently precludes using single donor samples and, additionally, 
single donor samples are limited by the possible presence of any interfering substances 
that may influence the MP and, hence, confound the interpretation of the analytical 
result. Pooled samples, on the other hand, are usually easy to obtain in the desired 
amount, and possible interfering substances are most likely diluted. Nevertheless, there 
is a possibility that substances in the pool might interact and, in turn, modify the matrix 
of the samples (55).  
Noklus obtains whole blood from healthy donors at the blood bank for the EQA 
material for the joint CRP, glucose, and Hb EQA scheme, and the material is also 
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pooled to reduce the chance of any interfering substances. However, some of the MPs 
analyzing glucose have been shown to be incompatible with the use of anticoagulants 
(ethylenediamine tetraacetic acid (EDTA), lithium heparin, or natrium heparin). Hence, 
serum EQA samples, also produced at Noklus, are circulated to a low proportion 
(0.5%) of the participants.  
Participants must be provided with samples in concentration ranges that are clinically 
relevant to ensure that the EQA materials are fit for use. However, using pooled 
samples from healthy people makes it challenging to obtain the concentration ranges 
needed for the particular analyte. This is especially true because the EQA materials 
include three measurands, and each is in two different concentrations. For CRP, which 
can increase over 100-fold in response to infection or inflammation, as well as for 
glucose, the concentration of the analytes in the healthy donor samples is too low to 
cover the clinically important decision points. The Hb concentration, on the other hand, 
which differs within the normal reference range of healthy individuals, might have an 
initial concentration that is either too high or too low for the desired level in the EQA 
material. Analytes can then be added or removed to achieve the preferred 
concentrations, or it may be possible to dilute the material (55). When spiking the EQA 
material with a simple and well-characterized analyte in a highly purified form, it is 
reasonable to believe that the matrix of the material will not be altered (55). However, 
increased complexity of the added clinical analyte increases the risk of changing the 
sample matrix and inducing noncommutability (93, 105). The particular analyte can be 
removed using a highly specific technique, or the material can be diluted using a 
suspension bearing similar matrix properties to obtain an EQA sample with a lower 
concentration (55). At Noklus, human native CRP with a purity > 70% (in.vent 
Diagnostica), and D(+)-glucose monohydrate (VWR) are used to achieve EQA 
samples with the desired concentrations. The material is either diluted using plasma or 
erythrocytes are added to obtain both low and high Hb concentrations.  
After production, the EQA material is divided into thousands of aliquots to provide 
each participant with two levels of EQA samples. The occurrence of between-bottle 
inhomogeneity can be induced, since aliquoting of large pools may take hours. At the 
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end of the production process, the homogeneity between bottles is evaluated by 
analyzing the concentration of CRP, Hb, and glucose from several bottles in the entire 
lot of aliquots produced. Ten bottles are evaluated in total to obtain a reliable 
assessment of the EQA material’s homogeneity, based on the lot size (106).  
After aliquoting, the EQA material is distributed to the Noklus participants by mail. 
Verification of the material’s short-term stability during shipment and throughout the 
analytical period is therefore needed. Noklus has two different approaches for testing 
the stability of the EQA samples. Using the classical laboratory method, ten EQA 
samples at each concentration level are exposed to room temperature for two days 
before being refrigerated for one week (9 days in total). The storage conditions are 
supposed to mimic the mailing and storage at the participating laboratories during the 
analytical period of the EQA scheme. The EQA samples, at both levels, are then 
analyzed ten times each day, and a statistical validation of the EQA material’s stability 
is then performed. The other method of assessing the EQA material’s stability is by 
using the participants’ results statistically and assessing whether time is a significant 
contributor to the variation seen between the samples. In the whole blood EQA 
material, keeping the glucose concentration stable is particularly challenging. 
Glycolysis starts immediately after the material is collected, and thereafter, the 
concentration of the glucose in the material decreases 5–7% per hour if the whole blood 
sample is left at room temperature (107). In an EQA scheme in which the analytical 
period lasts over a week, the material needs to be stabilized. The Noklus EQA material 
therefore has added iodoacetic acids sodium salt and chloramphenicol succinate to 
maintain the concentration of glucose and control microbial contamination in the 
samples (78). Adding such stabilizing materials may cause alterations to the sample 
matrix of the whole blood samples and may result in noncommutability (55).  
Making the EQA samples fit for use is a prerequisite, but it is also an intervention that 
may alter the matrix of the EQA material to such an extent that the samples are no 
longer representative of authentic patient samples (i.e., they are noncommutable).   
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1.6.2 Validating commutability 
Commutability is one of the most important characteristics of the EQA material. When 
commutability is not verified, a matrix-related bias may affect the MPs by an unknown 
magnitude, thereby restricting the EQA organization’s ability to evaluate the 
performance of the MPs and the participants. In the harmonization and standardization 
process, EQA schemes can be very useful for assessing and monitoring the agreement 
of laboratory results for the same measurand when using different MPs (108). 
However, data have indicated that EQA results may not always be useful due to matrix 
effects within the processed samples (55).  
In every chemical analysis, the analyte of interest is set in a compound of other 
substances, a sample matrix (79). The matrix effects may impact the sample, 
independent of the analyte, causing matrix-related bias and thereby influencing the 
analytical result by an unknown magnitude (108). Evaluating the performance of the 
MPs can be difficult, and in turn can lead to incorrect assessments of the analytical 
bias, which in turn can affect patient results if the MPs are adjusted based on incorrect 
data (108). The clinical consequence of matrix-related bias can be misclassification of 
risk or patients receiving inappropriate therapy (108). 
The ISO definition of a matrix is generic and comprises all sample materials, including 
clinical samples, and all endogenous substances, except the analyte (74). Matrix effects 
leading to noncommutability of the processed samples are a result of the interplay 
between many different components in the analytical testing procedure, for example, 
the design of the MP, the reagents, the sample processing technique, and the processed 
sample’s matrix (108). Matrix effects leading to noncommutability of the processed 
samples are a result of the interplay between many different components in the 
analytical testing procedure, for example, the design of the MP, the reagents, the 
sample processing technique, and the processed sample’s matrix (84). However, in 
practice, differentiating between a lack of specificity and matrix effects can be 
challenging (74). Interference caused by normally occurring endogenous substances in 
abnormal concentrations is in most cases not regarded as a matrix effect, however, 
nonnative forms of an analyte are considered a matrix effect (55). 
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ISO 17511 defines the commutability between a material and a set of clinical patient 
samples in relation to a chosen MP (79). The definition thereby refers to commutability 
as an MP-specific characteristic, hence, the EQA material can be commutable for some 
MPs, but noncommutable for others. Therefore, whether the EQA material can be used 
as a common trueness control depends on the number of MPs for which the EQA 
material is found commutable (55, 74). The causes of noncommutability are, thus, 
highly dependent on the MP, and the specific reasons leading to matrix effects and 
noncommutability may be difficult to predict. 
There are different consensus procedures in place for validating the commutability of 
reference materials and processed samples (86, 108). The CLSI has published 
guidelines in 2014, EP14-A3, Evaluation of Commutability of Processed Samples 
Approved Guideline-Third Edition, and in 2018, the IFCC Working Group on 
Commutability published three papers with recommendations. The first two papers are 
relevant for EQA organizations: IFCC Working Group Recommendations for 
Assessing Commutability Part 1: General Experimental Design, and IFCC Working 
Group Recommendations for Assessing Commutability Part 2: Using the Difference in 
Bias between a Reference Material and Clinical Samples (86, 109, 110). The 
establishment of mathematical relationships and assessing whether the results from the 
processed samples belong to the same distribution as the results obtained from 
authentic clinical samples when measured on a set of chosen MPs are common to both 
procedures (86, 108).  
The CLSI standard recommends the number and type of clinical samples that must be 
collected, indicates how they should be handled, how the analysis of the clinical 
samples and processed samples should be performed, and the number of replicates that 
is preferable. The CLSI advises the use of Deming regression for data analysis after 
performing tests to judge the utility of the statistical test for the dataset (outliers, 
linearity, variance, and homogeneity). The means of the triplicate measurements should 
then be plotted, and Deming regression should be carried out for each MP combination. 
A PI is calculated, and an assessment of the processed material can be performed (51). 
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An advantage of using Deming regression is that the method allows variability for both 
variables (74).  
In 2018, the IFCC launched guidelines for assessing commutability (86, 109, 110). The 
guidelines are a revised recommendation document in which two different statistical 
methods are proposed. The first method is recommended for processed materials 
intended to be used as calibrators, trueness controls, or EQA materials. The second 
method is suitable only when the processed material is intended to be used as a 
calibrator (109). The difference between the bias of the processed samples and the 
average bias of the clinical samples for all pairs of MPs are calculated using the IFCC 
method for assessing the commutability of an EQA material. Each of the process 
samples has error bars stating the uncertainty in the bias estimate, which is evaluated 
against predetermined fixed criteria indicating the maximum allowable bias. A 
processed material is assessed as commutable when the error bars are entirely within 
the allowable bias limits. MPs with large random errors will show increased scatter of 
the clinical samples and larger error bars of the processed materials and are, therefore, 
more likely to be assessed as noncommutable since the allowable bias limits are the 
same for all pairs of MPs examined. An evaluation of the MPs included in the 
commutability study should be done prior to the study to ensure that only MPs with 
adequate selectivity for the measurand are included. 
In general, the conclusions from the commutability study are only applicable to the 
MPs and reagent lots evaluated in the commutability study, therefore, ideally, all 
relevant MPs and reagent lots should be included. Nevertheless, since every 
commutability study in such a case had to be performed several times, depending on 
the number of reagent lots included, this is not realistically achievable. Both CLSI and 
IFCC recommendations, however, allow for assuming commutability for subsequent 
lots of processed materials when they are prepared in the same stringent manner (86). 
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1.6.3 Validating commutability of the EQA material for CRP, glucose, and 
Hb 
The whole blood prepared at Noklus is exposed to various alterations during 
production, hence, assessing the material’s commutability for the MPs (for which the 
samples are intended) is of great importance. The EQA material aims to act as a 
surrogate for authentic clinical samples. Therefore, individual clinical samples that 
were most likely to contain the matrix that the MPs intended to measure were collected 
for the commutability study. The number of samples gathered exceeded the minimum 
requirement, ensuring that there were sufficient data points for the statistical 
assessment. The clinical samples were selected with the intention of covering the 
measurement interval of the processed samples, not the total measurement interval of 
the MPs. This compromise is especially relevant for analytes with large measurement 
intervals, such as CRP, where obtaining clinical samples covering the entire 
concentration range is very challenging. The stability of the measurands is an important 
consideration in the selection of the method used to conduct the commutability study. 
In the current study, glucose was not sufficiently stable for prolonged storage and had 
to be analyzed without delay, so the experimental design therefore differed somewhat 
from the other measurands, since the collection and analysis was spread over multiple 
days. Noklus aims to include all the participants’ MPs in the commutability studies and 
therefore does not make exclusions based on (for example) precision or selectively of 
the measurands. However, if the number of MPs must be limited for practical reasons, 
the market share of the MPs will be the deciding factor. The details of the 




The overall purpose of the thesis was to evaluate the effect of participating in an EQA 
scheme, and to assess the EQA material used, for evaluating the participants’ analytical 
quality.  
Paper I 
The aim of the study was determining how the analytical quality of the u- albumin 
analysis in the GP offices in Norway developed between 1998 and 2012 in relation to 
the length of the participants’ involvement in the EQA and to evaluate what factors in 
the GP offices were related with good analytical quality. 
Paper II 
The aim of the study was to evaluate the effect of participation in a POC quality 
improvement system over time on the analytical quality of CRP, glucose, and Hb, and 
to determine which factors were associated with good participant performance.  
Paper III 
The aim of the study was to determine the commutability of the Noklus whole blood 
EQA material for CRP, glucose, and Hb for the most frequently used POC 
measurement procedures in primary healthcare in Norway, and to investigate the 
possibility of using a common EQA target value for each analyte.  
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3. Materials and methods  
3.1 Participants 
In paper I, EQA results from GP offices that participated in Noklus and performed the 
u-albumin measurement were included. The EQA scheme for u-albumin is circulated 
annually, and from 1998 to 2012, a total of 15 u-albumin EQAs were distributed to the 
participants.  
In paper II, EQA results from participants conducting either the CRP, glucose, or Hb 
measurements were included, i.e., GP offices, nursing homes, emergency primary-
healthcare facilities, family healthcare centers, and providers of home care and 
occupational healthcare. In some of the statistical calculations, home care and family 
healthcare centers were grouped as “others” since the groups contained relatively few 
participants. The analytes CRP, glucose, and Hb are covered by one EQA scheme 
distributed to the participants biannually. EQA results from 2006 to 2015, in total, 19 
EQAs, were included in the study.  
The following inclusion criteria were established for papers I and II. The specific MPs 
had to be used by more than eight participants, and the participants had to provide 
numerical results (not only a comment) to the EQA scheme. The participants who used 
quantitative MPs had to report results for both replicate measurements at both levels 
(four analytical results). In paper I, both semi-quantitative and quantitative MPs were 
included, and in paper II, all MPs involved were quantitative.  
Table 2 shows the number of years of participation, the number of EQAs, the average 





Table 2. Overview of data. The table shows an overview of the data included in paper I and II. Years 
of participation, number of EQA schemes, average number of participants in each EQA scheme, total 
number of EQA results. 
Paper Analyte Years EQA schemes (n) Participants (n) EQA results (n) 
I U-albumin 15 15 1159 69540 
II CRP 10 19 2134 162184 
II Glucose 10 19 2357 179132 
II Hb 10 19 2271 172596 
 
In paper III, no EQA participants were included.  
3.2 Measurement procedures 
In paper I, the semi-quantitative POC Clinitek MPs (four MPs) and the Micral-Test 
(one MP) were included along with nine quantitative POC MPs (Table 3).   
In paper II, 11 CRP, 41 glucose, and 18 Hb quantitative POC MPs were entered into 
the study.  
In paper III, the most frequently used POC MPs for CRP, glucose, and Hb were 
included in the study (i.e., five CRP, seven glucose, and five Hb MPs). Furthermore, 
the accredited hospital MPs Cobas 6000 (Roche Diagnostics, Switzerland) (CRP, 
glucose) and Advia 2120 (Siemens Healthcare GmbH, Germany) (Hb), both located at 
the laboratory at Haraldsplass Deaconess Hospital (Bergen, Norway), were entered into 
the study. The ERM/DA474/IFCC CRM (CRP) and the SRM 965b (glucose) were used 
to validate the trueness of Cobas 6000 in the commutability study. The Advia 2120 
(Hb) has good documented analytical quality through EQAs.  
Table 3. Overview of the POC MPs. Table 3 shows an overview of the included MPs and manufactures 












    Manufacturer     Measurement procedure     Measurement procedure version     Paper
    Siemens Healthcare Diagnostics
    Clinitek
    Status
I
    Status+
    50
    100
    DCA
    2000 Analyzer
    2000+ Analyzer
    Vantage Analyzer
    Roche Diagnostics GmbH     MICRAL-TEST
    Axis-Shield PoC AS
    Afini on AS 100 Analyzer
    NycoCard U-Albumin
    HemoCue AB     HemoCue
    Urine Albumin
    Albumin 201




    Axis-Shield PoC AS
    Afini on AS 100 Analyzer II, III
    NycoCard     CRP Single Test
II
    Reader II
    Orion Diagnostica
    QuikRead
    QuikRead
    101
    CRP 1 min
    GO II, III    CRP+Hb
    HORIBA Medical     ABX Micros
    CRP II
    CRP 200
II, III





    Roche Diagnostics GmbH
    Accu-Chek
    Aviva II    Nano
    Performa II, III
    Sensor
II
    Accutrend
    Sensor
    HemoCue AB     HemoCue
    Glucose 201
    Plasma calibrated
    Whole-blood calibrated
    DM RT
    RT
    Glucose 201+ 
II, III
    Plasma calibrated III
    Whole-blood calibrated
II    Glucose Analyzer
    Plasma calibrated
    Whole-blood calibrated
    Monitor
    Bayer Healtcare
    Ascensia
    Contour
II, III
II
    with Microfil
l
 REF 7085A
    with Microfil REF 7085
    Elite
    XL
    Contour
II, III
II    with Ascensia Microfil
l
 REF 7085A
    Next
II, III    XT
    Glucometer Elite II
    Abbott Diabetes Care Inc
    Freestyle
    Freedom Lite II, III
    Lite
II
    Medisense
    Precision Xtra     with Xtra plus
    Xtra with prec H
    Precision Xceed
    Xceed     with Xtra plus
    with prec H
    LifeScan Inc
    Gluco Touch
    One Touch
    Ultra
    Easy
    Smart
    2
    Vita
H
b
    Siemens Healthcare Diagnostics     Advia 60
II
    HemoCue AB     HemoCue
    B-hemoglobin
    Hb 201
    Hb 201+ II, III
    Hb 201 DM
II
    Orion Diagnostica     QuikRead     GO     CRP+Hb II, III
    HORIBA Medical     ABX
    Micros
    CRP II
    CRP 200 II, III
    Microsemi
II
    Boule Medical
    Swelab Alfa
    AutoCounter AC920
    EKF Diagnostic GmbH     HemoControl
II, III
    Sysmex Corporation     Sysmex
    PocH-100i
    K1000
II
    KX-21
    KX-21N
    Biotest Medizintechnik GmbH     Biotest Hemoglobin Tester
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3.2.1 EQA material 
The EQA material used in paper I was human urine acquired from volunteers with 
normal or increased excretion of u-albumin. The EQA material was manufactured at 
Noklus before being stored at -80C for a period of up to two years. Normal urine was 
added to the u-albumin urine before sterile filtration and separation into aliquots to 
achieve the desired concentrations. From 1998–2012 the u-albumin concentration in 
the EQA material was between 15 and 130 mg/L.  
The EQA material in papers II and III was AB0-compatible EDTA venous whole blood 
collected from healthy blood donors at the blood bank and stored in plastic bags 
(Haukeland University Hospital). At Noklus (Haraldsplass Deaconess Hospital), the 
whole blood was pooled, and plasma or erythrocytes were added to attain the desired 
Hb concentrations. Human CRP (in.vent Diagnostica) was added to obtain suitable 
concentrations of CRP, and D(+)-glucose monohydrate dissolved in sodium chloride 
(VWR) was added to achieve the intended glucose concentrations. Iodoacetic acid 
sodium salt (VWR) and chloramphenicol succinate (VWR) were used to stabilize the 
glucose concentration and prevent bacterial growth. In paper III, the whole blood EQA 
material was kept refrigerated overnight before being divided into 2 mL cryovials 
(Sarstedt) and stored at room temperature until the next day to resemble typical mail 
deliveries to the participants.  
In 2006, Noklus started producing its own in-house EQA material, which was 
subsequently distributed to all the participants analyzing POC CRP and Hb, and 53% 
of the participants analyzing POC glucose. The remaining laboratories that performed 
POC glucose received the commercial EQA material, Sugar-Chex Proficiency (Streck 
Laboratories). From 2006 to 2015, the concentration of the EQA material varied 
between 8–92 mg/L for CRP, 3–23 mmol/L for glucose, and 9–16 g/dL for Hb. For the 
commutability study in paper III, two concentrations of Hb and three concentrations of 
glucose and CRP were produced to cover the clinically relevant ranges. The following 
concentrations of the EQA material were produced for the study 23, 58, and 73 mg/L 
for CRP 7.0, 13.0, and 17.0 mmol/L for glucose and 9.6 and 13.2 g/dL for Hb.  
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The EQA material’s homogeneity and stability were documented in accordance with 
ISO 13528 (78).  
 
3.2.2 EQA surveys 
In the EQA schemes in papers I and II, each of the participating laboratories obtained 
two EQA samples at different concentrations by mail. The participants were asked to 
store the EQA materials in a refrigerator and then allow the samples to reach room 
temperature before analyzing each EQA sample on two separate days. The participants 
analyzed each EQA sample twice using quantitative CRP, glucose, Hb, or u-albumin 
MPs, while participants using semi-quantitative u-albumin MPs analyzed each sample 
once. Within six days, they reported their analytical results to Noklus, along with 
information about the POC MP used, the lot number, the expiration dates of the 
reagents, the profession of the person who performed the analysis, how often IQC was 
performed, and finally, the number of patient samples performed at the laboratory each 
week.  
 
3.2.3 Target values 
In the EQA schemes in papers I and II, method-specific target values, calculated as 
medians after excluding outliers more than ± 3 SDs from the median, were used to 
assess the participants’ performance for POC CRP, glucose, and Hb, in addition to the 
quantitative u-albumin MPs. For each of the two EQA material concentrations, the 
mean of duplicate measurements, calculated from the participants’ EQA results, was 
assessed as “very good” when the mean concentration of u-albumin was within 7% of 
the target interval (target value ± 2 mg/L), and “poor” for results exceeding 15% of the 
target interval. The CRP participants’ results were assessed as “good” when the mean 
concentration of CRP was within the target interval (target value ± 2 mg/L) ± 8% and 
“poor” for results exceeding the target interval ± 15%. Glucose participants were 
evaluated as “good” when the mean concentration of glucose was within 5% of the 
target interval (target value ± 2 mg/dL [±0.1 mmol/L]), and “poor” for results 
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exceeding 10% of the target interval. Hb participants were evaluated as “good” when 
the mean concentration of Hb was within the target interval (target value ± 0.1 g/dL) ± 
3% and “poor” for results exceeding the target interval ± 8%. The participant 
performance was evaluated as “acceptable” for results between the limits for “poor” 
and “good” for all three analytes.  
Participants using semiquantitative MPs reported their results in one of four possible 
categories. The category containing >30% of the semi-quantitative answers was used 
as the target value and represented the “good” category, the next category was labelled 
“questionable” and the remaining two categories were labelled “poor”. 
In the statistical analyses in papers I and II, participants were characterized as “good” 
when they acquired assessments of “good” on both EQA samples, “acceptable” when 
they received an assessment of “acceptable” on one EQA sample and an “acceptable” 
or “good” assessment on the other, and “poor” for all other result combinations. 
 
3.2.4 Patient samples and measurements 
In paper III, the procedure for evaluating the commutability of a whole blood EQA 
material, delineated in the CLSI Guideline EP14-A3, was utilized (108). In agreement 
with the guideline document, the patient samples were gathered to cover the 
concentration range of the EQA material (Haraldsplass Deaconess Hospital). 
Altogether, 22 CRP, 23 glucose, and 25 Hb patient samples were collected. The CRP 
and Hb samples were leftovers from routine specimens at the laboratory, while the 
glucose samples were fresh capillary whole blood samples collected from healthy 
volunteers or volunteers diagnosed with diabetes mellitus. The glucose specimens were 
sampled by a biomedical laboratory scientist in a predetermined order to attain patient 
samples for both the POC MPs and the hospital MPs, the sample for the hospital MP, 
followed by samples for the POC MP, and then the sample for the hospital MP. Before 
and after each measurement sequence, IQC was performed on all POC MPs. 
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In compliance with EP14-A3, triplicate measurements of the patient samples with the 
EQA material randomly interspersed were performed on both the MPs for the POC and 
the hospital. EDTA blood was used for all the measurements performed on POC MPs, 
in addition to the analysis of Hb for the hospital MP. Serum was used for the analysis 
of CRP and glucose for the hospital MP. The patient samples were measured directly 
after collection, while the EQA material was analyzed two days after production, which 
included overnight storage at room temperature to imitate the mail delivery of the EQA 
samples to the participating laboratories. All measurements were performed at Noklus 
(POC MPs) and at the laboratory of Haraldsplass Deaconess Hospital (hospital MPs). 
 
3.2.5 Statistics 
In papers I and II, cross-tabulations and odds ratios (ORs) were calculated to evaluate 
the impact of performing the EQA. The EQA results categorized as “good” were 
compared to the results categorized as “poor” or “acceptable”, and a two-sided chi-
squared test and a Fisher’s exact test were used for the computations. The level of 
statistical significance was set at p < 0.05. 
In paper I, logistic regression was applied to each EQA survey. The participants’ 
trueness and precision assessments were dependent variables, and the independent 
variables were the MP used, frequency of IQC, the profession of the employer 
performing the analysis, the number of GPs working at the GP office (until 2006), and 
the number of analyses performed at the laboratory each month (from 2009). The cutoff 
for statistical significance was set at p < 0.05.  
In paper II, a binomial logistic regression was carried out after transforming the 
participants’ assessments into a binary variable to compare good performance to 
poor/acceptable performance. The independent variables covered in the analysis were 
the number of participants in an EQA scheme, the type of participant, the profession of 
the employee analyzing, the number of analyses conducted each week, the frequency 
of performing IQC and when IQCs were performed, whether the MP was changed, and 
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the expiration dates on the reagents used. The cutoff for statistical significance was set 
at p < 0.05. 
In paper III, the statistical analyses of the commutability of the EQA materials were 
conducted in accordance with the EP14-A3 guideline. First, outliers within the 
triplicate measurements were excluded from further analysis, then the homogeneity of 
variance was evaluated and, if applicable, the results were log10-transformed. The 
linearity between the paired MPs was assessed visually before difference plots were 
displayed for every MP combination, and a log10 transformation was utilized when 
required. Finally, outliers between the MPs were excluded. Deming regression analysis 
based on the mean of triplicate patient sample measurements (log10-transformed or 
untransformed values), was performed for each analyte and each MP combination. A 
95% PI was calculated and plotted graphically, together with the mean values from the 
triplicate measurements of the EQA samples. The EQA material was considered 
commutable if the means of each of the EQA samples were within or touching the PI 
limits, otherwise, it was regarded as noncommutable. 
The calculations were performed using Excel (version 14.4.8), SPSS (version 19.0, and 
22.0), and the following packages of the software R (version 3.1.2, R Development 
Core Team, 2007): mcr (method comparison regression, version 1.2.1), methComp 
(functions for analyzing the agreement in method comparison studies, version 1.22.2), 




4.1 The quality improvement system’s effect on participant 
performance 
In papers I and II, the percentage of participants who obtained a rating of good 
performance increased, and there was a similar decrease for those with poor 
performance, for all analytes assessed. The length of time the participants had been a 
part of the Noklus quality improvement system seemed to have an influence on their 
performance. 
In paper I, the percentage of GP offices receiving an assessment of good or poor 
trueness increased and decreased, respectively, and seemed to be influenced by the 
length of time they had participated in EQA (Figure 9A and Figure 9B). When 
comparing old to new participants, the OR for receiving the assessment of good 
trueness compared to poor trueness generally increased the longer the GP office had 
participated in the EQA (i.e., comparison of participation for the third and ninth times 
yielded ORs of 1.5 [95% CI: 1.1–2.1] and 4.2 [95% CI: 2.2–7.8], respectively). 
Significantly more old participants, unlike new participants, were assessed as good 
compared to poor for precision (OR: 1.5 (95% CI: 1.2–1.8)).  
In paper II, the percentage of participants with an assessment of good trueness on the 
CRP analysis increased from 73% to 90%, while the percentage of participants with 
poor trueness assessments decreased from 12% to 3%. For glucose, good trueness 
assessments increased from 69% to 83%, and poor trueness assessments decreased 
from 10% to 3%. For Hb, the number of good trueness assessments increased from 
88% to 94%, and the number of poor trueness assessments decreased from 3% to 0% 
after performing EQA for the first and nineteenth times, respectively (Figure 9A and 
Figure 9B). The overall OR for receiving good performance versus poor performance 
for participants who had taken part in a minimum of two earlier EQAs, compared to 
participants who were taking part for the first time, were 2.12 (95% CI: 1.66–2.70) for 




Figure 9. Participation over time. The figures show good participant performance in relation to number 
of years participating in EQA. The blue line shows u-albumin (15 EQAs), the red line shows CRP (19 
EQAs), the green line shows Hb (19 EQAs), and the purple line shows glucose (19 EQAs). In Figure 
9A the y-axis ranges from 0-100% whilst in Figure 9B the y-axis ranges from 65-100%. The figures 
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4.2 Factors associated with good participant performance 
In paper I, it was concluded that participants using quantitative MPs who obtained a 
poor trueness assessment received significantly fewer poor trueness assessments the 
year after changing their MP, regardless of whether they chose another edition of the 
same MP or a new type of quantitative MP. The change in MP resulted in significantly 
fewer good trueness assessments for participants who initially obtained an assessment 
of good trueness. Participants who used quantitative MPs involving reagents with over 
three months left before their expiration date, performed significantly better than those 
using reagents expiring within three months (p < 0.001) or reagents that already had 
expired (p < 0.001). 
Several practice characteristics changed significantly between 1998 and 2012. The 
percentage of participants who never performed IQC decreased from 48% to 6%. The 
percentage of participants choosing a quantitative MP (DCA) increased, and the 
percentage choosing a semi-quantitative MP (MICRAL–TEST) decreased. The DCA 
MPs performed better than each of the other quantitative MPs for both trueness and 
precision. The profession of the operator, the frequency of IQC, the number of GPs at 
the GP office, and the number of analyses performed each month did not significantly 
influence the participants’ assessments. 
In paper II, a logistic regression analysis was implemented with a binary variable for 
good versus poor/acceptable performance. The study identified a number of 
independent factors that were associated with good participant performance, 
performing EQA more than once, the operator was a medical laboratory scientist, 10 
or more analyses were performed each week, there was weekly IQC, and the kind of 
MP that was used. For CRP and Hb, the GP offices performed significantly better than 
the other participants, whereas nursing homes performed best in the EQA regarding 
glucose. The participants using reagents with more than 60 days until their expiration 
date performed significantly better than participants using reagents with 60 or fewer 
days until the expiration date of their reagents in the EQAs for glucose and Hb. Whether 




Figure 10. The figure illustrates which variables characterized good participant performance.   
 
4.3 Commutability of the EQA material 
When the CRP and Hb POC MPs were compared with the hospital MPs, the EQA 
material was commutable for all combinations except for the QuikRead GO at the 
highest concentration of CRP (Table 4).  
For glucose, the EQA material was commutable between the hospital MPs and all POC 
MPs at the lowest concentration. For the two higher concentrations, commutability was 
only demonstrated for the Contour and HemoCue MPs (Table 4).  















Pairwise comparisons of the POC MPs revealed that the EQA material was 
commutable for nearly all combinations for CRP and Hb. For glucose, 37 of 63 
combinations showed commutability, mainly at the lowest concentration.  
 
Table 4. Commutability of the EQA material. The table shows for which MP combinations the EQA 
materials was commutable (green) and noncommutable (blue). Only POC MP in combination with the 
hospital MPs is shown.  
Commutable 
Noncommutable  
Hemoglobin 9.6 g/dL 13.2 g/dL 
Measurement procedure Advia 2120 Advia 2120 
ABX Micros CRP 200   
HemoControl   
HemoCue Hb 201+   
Sysmex PocH-100i   
QuikRead GO CRP + Hb   
CRP 23 mg/L 58 mg/L 73 mg/L 
Measurement procedure Cobas 6000 Cobas 6000 Cobas 6000 
ABX Micros CRP 200    
Afinion AS 100 Analyzer    
i-Chroma    
NycoCard CRP Single Test    
QuikRead GO CRP + Hb    
Glucose 7 mmol/L 13 mmol/L 17 mmol/L 
Measurement procedure Cobas 6000 Cobas 6000 Cobas 6000 
Accu-Chek Performa    
Ascensia Contour    
Contour    
Contour XT    
FreeStyle Freedom Lite    
HemoCue Glucose 201+    
HemoCue Glucose 201RT    
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5. Discussion 
The present thesis evaluated participants’ assessments in different EQA schemes over 
time and assessed which factors are associated with good performance. Additionally, 
the commutability of the whole blood EQA control material used for the EQA scheme 
was examined. 
5.1 Methodological considerations 
5.1.1 The observational descriptive studies 
Study population 
In paper I, GP offices performing u-albumin analysis were included in the study. The 
EQA scheme for u-albumin at Noklus, however, includes analysis of both, participants’ 
u-albumin and u-albumin/creatinine ratio. An important aim of the study was to make 
use of Noklus’ data to assess the variables associated with good performance. For the 
u- albumin analysis, 14 different MPs took part throughout the entire study period 
compared to only one MP analyzing the u-albumin/creatinine ratio in the same time 
interval. The type of MP used by the participants was expected to be an important 
variable affecting performance, and hence, u-albumin data were chosen for further 
analysis in study.  
In paper II, all participants performing either CRP, glucose, or Hb measurement in 
primary health care in Norway were included, GP offices, nursing homes, emergency 
primary-healthcare facilities, family healthcare centers, and providers of home care and 
occupational healthcare. Different analytes and participant types were included, which 
increased the overall data set and allowed the evaluation of the potential differences in 
performance between analytes and types of participants. The study period included data 
from 2006 to 2015. In 2006, Noklus started producing their own in-house whole blood 
EQA material for the joint CRP, glucose, and Hb EQA scheme. Limiting the participant 
results to the same EQA material reduced the heterogeneity of the study group and 
increased the reliability of the study design as the EQA material is an essential 
component of the scheme and studies. If the EQA material were to differ among the 
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study groups, it would be difficult to recognize real differences in participant 
performance, which, however, can be related to the importance of commutability of the 
EQA material when assessing differences in the performances of MPs.  
To be included in the studies in paper I and II, the participants’ MPs had to be used by 
at least 8 participants. This criterion is routinely used in the EQAs at Noklus when a 
method-specific target value is calculated to reduce its uncertainty. In the studies, the 
overall participant performance was used as the dependent variable and to ensure 
reliability only participants reporting numeric results on both replicate measurements 
at both levels (four analytical results) in the EQA scheme was included.  This inclusion 
criterion provided a more reliable estimate of the participants’ performance and made 
it possible to obtain an estimate of the MPs precision. The number of participants 
excluded due to these selection criteria was, however, negligible, and therefore, 
practically all participants in the Noklus EQA schemes for u-albumin, CRP, glucose, 
and Hb were included in the respective studies. The amount of data (nearly 600 000 
analytical results in total), along with the knowledge that 99% GP offices and 96% 
nursing homes in primary care are enrolled in Noklus, resulted in a large cohort of 
participants included in the respective studies and an increased likelihood for the data 
being representative of primary-care laboratories in Norway. In addition, there should 
be no selection or information bias in the dataset because nearly all participants were 
included, providing the same set of information. Based on the population included, the 
external validity of the studies was considered to be strong. 
 
Participating in EQA scheme over time 
There have been, as abovementioned, concerns about the management of POC quality 
in primary care (111-115). Its importance, however, has also been recognized, and in 
paper I and II in this thesis, the effect of quality management of POC in primary health 
care has been evaluated. The performance in EQA over time was assessed using an 
observational study design. The retrospective studies were conducted using data from 
already performed EQAs for u-albumin, CRP, glucose, and Hb. The participants’ 
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overall performances on the different EQAs were linked to the unique laboratory 
number, making it possible to observe the effect of participation in EQAs over several 
years. A recent review by Price et al., in which whether quality management of POC 
testing leads to better test results was evaluated, identified five studies, all 
observational in nature, in which the performance of POC testing in EQAs was used to 
evaluate the improvement over time (8).  
The study designs for paper I and II were chosen to benefit from the extensive set of 
data Noklus acquires on EQA schemes in primary care in Norway. Noklus is, in fact, 
one of few organizations worldwide in possession of EQA data covering such a long 
period of time. Characteristics of the dataset favoring comparability throughout the 
entire study period and the reliability of data were the similarities in the obtained 
information from the participants, and the unaltered APS made the participants’ 
assessments comparable from one year to another. The study design enabled us to 
follow the participants retrospectively over a relatively long period of time and allowed 
us to find long-term patterns in their performance.  
In paper I, the performance in EQA over time was assessed by comparing old and new 
participants using the OR. Factors associated with good analytical quality were 
changing MP when the initial performance was assessed as poor and using reagents 
that were not expired or had more than three months left to the expiration date. 
Observational studies, however, run the risk of confounding bias, which might affect 
the outcome of the study. Confounding was addressed further in paper II, in which 
logistic regression analysis was performed to assess whether the variables were 
independent predictors for good participant performance. The regression identified the 
number of participations in the EQA, performing IQC weekly, performing more than 
10 tests weekly, using recommended MPs, and having laboratory qualified operators 
as independent predictors for good participant performance. Although these variables 
are important aspects registered in the EQAs by Noklus, they are not necessarily the 
only variables contributing to good performance. As opposed to experimental studies, 
in retrospective observational studies, you have a lower ability to control for 
confounders. Factors other than those included in the estimation model could 
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potentially influence the performance, e.g., participation in courses or training of the 
operators, which, due to lack of data, was not included in the analysis (116). 
Participation in courses or training is one example of threats to the internal validity, 
where something else besides the participation in the EQA scheme accounts for some 
of the observed improvement. Such factors could be specific events, as in the case of 
participation in training, or they could be part of a process of growth and spread of 
information and knowledge over time. Because the research was conducted in a real-
world setting, the data collected would, naturally, be affected by an increasing number 
of old participants compared to new participants the longer the study lasted, and the 
old participants would also, in general, have their performance recorded later in time 
than the new participants. If there is a time trend of continuous improvement that is 
unrelated to participation in EQA schemes, in the dataset, the participant performance 
would be expected to improve with an unknown magnitude independent of the EQA 
schemes distributed. The time variable was, however, assessed by evaluating whether 
the number of good participant performances gradually increased with each EQA 
distributed. The percentage of good performances showed, on contrary, an irregular 
curve with no obvious time trends. Furthermore, all data available in the EQA database 
were considered to increase the internal validity of the study.  
In paper I and II, the same participants’ continuous measurements in primary care were 
studied over 15 and 9 years, respectively. A prerequisite for the statistical tests used 
was that the observations were independent because ordinary regression models do not 
consider any possible dependency between repeated measurements. An alternative to 
the logistic regression model used in study II was to use other statistical methods used 
in longitudinally observational studies like generalized estimated equations (GEE) or 
the mixed effects model. These models take into account an unknown correlation 
between the measurements. In addition, cluster analysis could have been performed to 
evaluate whether some groups of objects in a study are more similar than objects in 
other groups. However, since the participants were GP offices, nursing homes etc., and 
not the same individuals, the data were, after discussions, presumed to be independent 
of each other. Additionally, Noklus emphasizes in the EQAs that the EQA material 
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should be handled and analyzed as routine samples, and measurements are to be 
performed by different employees normally performing the POC testing.  
An alternative approach to the descriptive study design would have been to include a 
comparison group and performing an experimental study to evaluate the data using two 
randomized cohorts. Then, the effect of participation in EQAs, different independent 
variables, the time trend, and potential confounders could have been more closely 
scrutinized. Such a design would, however, be impractical as 99% of all GP offices and 
96% of all nursing homes in Norway at the time of the studies already took part in the 
EQA voluntarily, and a control group would consequently be difficult to establish. An 
alternative could be to let some of the EQA participants take part in the EQA scheme 
but not receive feedback on their results, nor been followed up in cases of poor 
assessments. An evaluation of the control groups’ assessments compared to the ones 
receiving feedback and support could then be performed. Such a study design would, 
however, be impractical as Noklus’ data could not be used to its full potential because 
the participants would have to be followed up in a prospective study. Additionally, the 
study design would be unethical. Provided the EQA schemes are performed to ensure 
laboratory quality and patient safety, knowledge regarding poor POC test results in a 
facility without intervening in the name of research could potentially lead to patient 
harm, which is the opposite of what the current research intended to do. Finally, to be 
able to assess differences between new and old participants, the study design, in our 
case, had to be retrospective. Because the larger share of primary care today takes part 
in EQAs, results from new participants could only be obtained by gathering data from 
when EQA was first introduced in Norway. In addition, to follow the participants over 
such a long period of time and assessing whether there is an improvement in the POC 
quality over time, not only whether there is an effect, a longitudinal observation study 
is the preferred study design.  
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5.1.2 The CLSI EP-14-A3 standard for evaluating commutability 
The commutability of the whole blood EQA material was examined utilizing the 
guidelines designated in CLSI EP-14-A3 (108).  
 
Measurement procedures 
In paper III, the most commonly used POC MPs for CRP, glucose, and Hb in primary 
care in Norway were included in the commutability study. Ideally, all MPs used in an 
EQA scheme should be covered for in such a study to verify whether the EQA material 
is commutable for all POC MPs for which the EQA material is ought to be used (55). 
Furthermore, the CLSI standard recommends that every new batch of EQA material 
produced is tested for commutability. Performing a commutability study is, 
nevertheless, both time consuming and costly, especially in cases where whole blood 
EQA material is distributed to the participants. The batch of whole blood EQA material 
then needs to be freshly prepared prior to each EQA scheme. If the recommendations 
of testing every new batch and every new MP were followed, several commutability 
studies had to be performed yearly. A reasonable approach, which has also been used 
by Noklus, has been to test the most commonly used MPs in the EQA scheme and 
assume commutability of new batches of the EQA material, provided they are prepared 
in a similar manner (55). To cover for the most commonly used POC MPs in primary 
care for the analytes, five MPs for CRP and Hb and seven MPs for glucose were 
included in the commutability study. The proportions of participants using one of these 
MPs in the EQA scheme at the time of the commutability study were 98%, 87%, and 
97% for CRP, glucose, and Hb, respectively. The external validity of the commutability 
study was therefore regarded to be strong.  
When assessing the commutability of the POC MPs, it can be an advantage to have a 
comparative MP for evaluation. Ideally, the comparative MP should have minimal 
matrix effects, and a reference MP is therefore preferable (117). For CRP, there is 
currently no reference MP, and the hospital MP, Cobas 6000, was therefore included 
in the commutability study along with the CRM ERM/DA474/IFCC CRM (94). The 
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glucose and Hb results are, on the other hand, traceable to the reference MPs ID GC-
MS and HiCN, respectively (61, 101). The two reference MPs could, in theory, have 
been included in the commutability study. For glucose, however, method-specific 
target values are still used in the EQAs. The systematic bias is, however, calculated for 
MPs for which the EQA material has shown commutability and, in this process, Cobas 
along with the certified reference material NIST SRM 9965b is used. For Hb, the target 
value for the EQA material is established using the HiCN reference MP in Odense 
university Hospital (Odense, Denmark). For practical reasons, however, the frequently 
used hospital MP Advia 2120 was chosen as the designated comparison MP. Because 
the patient samples were to be analyzed freshly on both the POC and the designated 
comparison MPs, it was not possible to include the reference MP in the commutability 
study for comparison. The CLSI guidelines also argue for using a validated hospital 
MP in cases where a reference MP is not practical (117). Nevertheless, Advia has 
shown good analytical quality when assessed in EQA schemes, where a true value has 
been used. Consequently, there is no reason to believe the results from the 
commutability study are not valid. 
 
Preanalytical challenges 
The patient samples needed for CRP and Hb measurements could be collected from 
leftover routine samples, and after collection, they were freshly analyzed as a single 
batch within one day, which is recommended by the CLSI standard. For the analysis of 
glucose in fresh capillary blood samples, however, some adjustments had to be made 
to overcome the preanalytical challenges mainly associated with stability (118). The 
patient samples for the glucose study were, therefore, collected and analyzed over six 
days, which may have influenced the day-to-day variation. Several efforts were, 
however, undertaken to minimize the variation and help in maintaining the internal 
validity of the study. An experienced biomedical laboratory scientist performed sample 
collection by following current guidelines and analyzed the samples in the exact same 
order in every measurement sequence (119). The punctation site was heated prior to 
punctation to avoid squeezing which, as abovementioned, is one of the most common 
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confounding factors in capillary blood sampling. Furthermore, the first blood drop was 
discharged. The glucose samples that were to be analyzed on the hospital MP were 
immediately centrifuged and frozen to avoid glycolysis and a decrease in the glucose 
concentration. There have, however, been concerns that freezing might change the 
clinical samples’ matrix (67, 120). Freezing could then have altered the matrix of the 
hospital samples, making the samples not comparable to the samples analyzed directly 
on the POC MPs. To limit the differences and maintain the validity of the study, plasma 
was frozen at -80°C for a short time and the procedure was performed in accordance 
with the National Institute Standards and Technology’s protocol for storing CRMs 
(121). The plasma samples were also, as recommended by CLSI, analyzed on a single 
day to prevent any day-to-day variation influencing the data, which increased the 
validity of the study (108).  
IQC was performed on all POC MPs before and after each measurement sequence. 
Finally, all cuvettes had the same lot number to prevent lot-to-lot variation because 
studies have indicated that noncommutability may occur between lots (122, 123). It is, 
nevertheless, important to emphasize that the recommendations from CLSI do not 
address the analyte per se but are general recommendations on how to perform a 
commutability study.  
 
Statistical power 
The CLSI 14-A3 recommends obtaining at least 20 patient samples for the 
commutability study, in the current study, 22 CRP, 23 glucose, and 25 Hb samples 
were collected. The patient samples and the number of replicates is important for the 
statistical power, i.e., the probability for determining whether the EQA material is 
commutable or not, and thus, for the internal validity of the study. The number of 
samples and replicates have been increased in studies to evaluate the effect on PI (124). 
The results, however, did not show narrowing of the PI, but an increased confidence in 
the PI obtained (124). Other methods like virtual pooling or calculations of the 
statistical power to determine the sufficient samples size have also been suggested to 
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improve the statistical power (124, 125). Although an increased number of samples or 
replicates could have increased the power of the study, 20 to 25 patient samples were 
the number of clinical samples that was practically achievable considering the 
recourses of the study and the number was sufficient following the advice of the CLSI 
guidelines (108).  
 
Assessing commutability 
According to the CLSI standard, a visual assessment of the variance of homogeneity, 
the linearity between MPs, and the degree to which the SDs increased with increasing 
concentration should be performed (108). These assessments are, as a result, to a certain 
extent, subjective. This is also the case when evaluating the Deming regression plots 
as the EP14-A3 standard does not give any guidance on how to interpret such data 
points or how many must fall within the PI’s limits for the EQA material to be 
considered commutable overall. Difficulties arise particularly when the values of the 
EQA material fall on or close to the PI’s limits. In such cases, the individual judgement 
can affect the outcome of the commutability study and thereby affect the study’s 
validity. To increase the reliability of the study design, common rules for evaluating 
the data points were established. First, data points located on the prediction lines were 
assessed as commutable, whereas data points right outside, not touching the prediction 
lines, were assessed as noncommutable. Second, each of the EQA material’s data 
points in one Deming regression plot had to be assessed as commutable for the EQA 
material to overall be assessed as commutable for the particular MP couple. In addition, 
all MP couples were discussed in plenary to ensure reliability. Our assessments on 
commutability in the current study, however, seemed to be in concordance with other 
studies on the evaluation of commutability using the CLSI guideline (126).  
Noncommutability for the EQA material was primarily observed at the high 
concentration of glucose. Because Deming regression is a linear model, the regression 
line and, therefore, the PI, is determined by all the data points in the selected 
population. As the patient samples, in general, were dominated by samples with low 
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concentration of glucose, the regression line and, consequently, the PI, could be more 
appropriate for assessing EQA materials at a lower concentration range. Similar 
findings were also observed in a study by Liu et al. (127). To increase the validity of 
the study, one should aim to have approximately the same number of patient samples 
at all concentration levels. However, in practice, this may be challenging when the 
patient samples are to be collected fresh and spiking must be avoided. 
In 2018, the IFCC working group on commutability launched the IFCC difference in 
bias approach for assessing commutability of reference and EQA materials (86, 109, 
110). In contrast to the CLSI method that utilized the statistical distribution of patient 
results when comparing two MPs to each other, the new recommendations suggested 
evaluating the disagreement in bias between the patient samples and the EQA material 
and, additionally, calculating error bars for uncertainty (18). Using error bars could 
have been an advantage in our study as the assessment of data points located on or near 
the PI limits could have been easier. A standardized way of assessing such data points 
would have increased the validity of the study. When using the CLSI method, 
calculating the limits of the PIs depended on the width of the scatter of the clinical 
samples and, thereby, the random error of the measurements from each MP. The criteria 
for whether the EQA material was assessed as commutable would, therefore, differ 
with the MPs evaluated. The IFCC difference in bias method recommends applying 
fixed limits based on medical requirements. The method also suggests only including 
MPs documenting the acceptable precision and selectivity since a large imprecision 
would result in wide error bars, making the commutability assessment inconclusive. 
Though it is a key limitation of the CLSI method that it is more stringent for precise 
MPs compared to less precise MPs, excluding MPs can be problematic. It is therefore 
possible that different criteria should be used for evaluating commutability of CRM 
materials and EQA materials. If a MP holds a significant market share and is widely 
used by the EQA participants, excluding the MP from the study would make the results 
less valuable both for the EQA provider and the omitted participants and would 
decrease the internal validity of the study (128). In addition, focusing on medically 
relevant differences can be of great importance when assessing the agreement between 
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MPs or evaluating the commutability of reference materials or calibrators, however, it 
may not be of equal importance when evaluating the commutability of EQA materials. 
For EQA materials, in our opinion, the key focus should be on whether the EQA 
material behaves similarly or different to native patient samples routinely analyzed by 
the participants.  
When medical requirements are used as criteria, they should ideally be based on 
outcome studies, c.f., the Milan criteria (66). Due to limited access to outcome studies, 
the APS used in laboratories are often based on biological variation, which are not 
based on medically relevant differences. In addition, using APS based entirely on 
biological variation may, for some analytes, be too strict, especially when evaluating 
EQA materials. The APS should, therefore, as mentioned earlier, take unique variations 
for EQA materials into consideration. Two studies recently assessed the commutability 
by applying both the CLSI and the IFCC methods (127). Whereas the first study, 
assessing a whole blood HbA1c CRM, concluded that the two methods gave overall 
consistent results, the second study, assessing serum sodium and potassium, obtained 
a large share of inconclusive results using the IFCC bias approach compared to the 
CLSI standard (127, 129). One of the main reasons underlined by the authors is the 
medical requirement criteria being too strict, which has also been argued by others 
(130, 131). Although none of the methods may be ideal for assessing the commutability 
of different materials, in our case, the IFCC method was not available at the time of the 
study and, therefore, only the CLSI standard was applied in the commutability study.   
5.2 Main results and implications 
POC testing has, in recent years, become increasingly available and especially with the 
current Covid-19 pandemic, rapid tests have been a key to quick tracing, isolating 
contacts, and helping break the transmission chain. Governments around the globe are 
spending billions on testing and tracing for Covid-19. One example is the UK 
government, which so far has spent over £10bn alone (132). To help stop outbreaks 
early and to ease lockdown restrictions, the UK is also offering free rapid tests for 
everyone across the country to be tested twice a week. For POC tests to be fit for 
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purpose, they must be both reliable and effective, not only in the laboratory setting of 
the manufacturer but in the range of different locations where the POC tests are 
performed. To recurrently ensure the quality of POC testing in the real-life setting, 
EQA schemes are used to assess the performances of participants and the MPs, and to 
enable this assessment, the quality of the EQA material is crucial (133, 134).  
 
5.2.1 Participating in EQA over time 
POC testing is typically performed outside the laboratories, near the patient. However, 
it is still defined as laboratory testing and should be treated as such. The entire testing 
loop must therefore be applied also to POC testing, including all aspects from the pre-
preanalytical to the post-postanalytical phases.  
The main focus of EQAs is to verify that the analytical quality conforms to the 
expectations for the quality needed for patient care (55). The scope of the EQA 
organizations has, however, also expanded to include both pre- and postanalytical 
components (55). Noklus comprises such a total quality system to cover the entire 
testing loop for POC in primary health care in Norway (75).  
In paper I and II, data from Noklus were evaluated to assess whether performance in 
EQAs over time resulted in improved quality. The analytical quality of the participants’ 
performances was used as the study outcome, and for all four analytes, the data showed 
a gradual increase in the number of participants who achieved good performance in the 
EQAs. Correspondingly, a decrease was observed for the number of participants whose 
performances were poor. The number of times a participant participated in EQA was 
also recognized as a key factor associated with good performance. Although EQA is 
recognized as an essential part of the laboratory’s quality management, relatively few 
studies have addressed whether participation in EQAs over time can give rise to 
improved quality. A systematic review from 2018 identified five studies using valid 
outcome measures to evaluate whether performance in EQAs improved the quality of 
POC testing in primary care (8). Three of these studies were performed at Noklus, two 
of which were a part of this thesis. In all studies, relevant outcome measures were 
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established by creating summary performance criteria, which were based on the 
participant’s EQA results assessed against predefined APS. In two of the studies, the 
imprecision of POC MPs was evaluated after participation in EQAs over 3, 5, and 9 
years, respectively, to the performance of the central laboratory. Both studies showed 
a decrease in the MP imprecision throughout the study period and concluded that the 
POC performance after the study period was equal to the one at central laboratories 
(135, 136). In the third study of Sølvik et.al performed at Noklus, two POC MPs for 
HbA1c were evaluated on whether they met specified target values for both bias and 
imprecision (137). The study found an improvement over time and concluded that the 
participants had about 90% probability of meeting the quality specifications when one 
MP was used (137).  
Including trueness as a study outcome when evaluating performance in EQAs over time 
is a strength. Because the number of replicates in the EQAs often are limited, the 
trueness is often a more reliable measurement than the CV, especially in cases where 
there is a true target value, like for Hb in paper II. Another reason for the trueness to 
be a robust outcome measure is the fact that the target value, and thereby the trueness 
result, is unknown for the participants. If one of the two replicates show a very 
divergent result, it may be more likely that the participants reanalyze the samples due 
to lack of precision than due to lack of trueness. This may also be linked to the 
Hawthorne effect, which may occur because of people know they are being watched 
(138). However, participating in Noklus EQAs is educational and not required for 
accreditation. In addition, the EQA material is distributed to the participants frequently, 
and Noklus emphasizes in the schemes that the samples are to be handled like routine 
clinical samples. 
Another strength of the studies in paper I and II is the fact that the same EQA material 
was used throughout the study period. Similar studies have mixed EQA results from 
different EQA schemes and different EQA materials, both liquid and lyophilized (136, 
139). As indicated in these studies, processed EQA materials may have unknown 
changes in their matrix, which may cause them to behave differently on different POC 
MPs (67, 74). The issue concerning matrix effects and commutability of the EQA 
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materials at Noklus was addressed in paper III of this thesis. Because the EQA material, 
at the time of the study of papers I and II, did not have documented commutability, the 
observed improvement was related to an improvement in participant performance or 
the between participant variation for one MP over time. In the case the EQA material 
was known to be commutable, the improvement reported in the studies would also 
reflect an improvement in the MP performance over time. Because four different 
analytes were assessed in the studies, it was possible to evaluate whether the effect of 
participation applied to different analytes and to what extent the effect was applied. 
Interestingly, the effect was not so much pronounced for Hb, which had a less of an 
increase in good performance. The participant EQA results for Hb have, for several 
years and through the entire study period, been evaluated against a true value. This has 
probably resulted in standardization and harmonization of Hb results, and the effect of 
participating in EQA schemes may therefore be more pronounced for analytes that do 
not have calibration traceability to a reference MP.  
One of the main benefits of using POC is reduced TAT, which in turn may lead to 
faster diagnosis and treatment and may thereby reduce referrals to secondary care (140, 
141). In some cases, it seems that using POC testing can lead to better patient care 
compared to hospital laboratory testing, as exemplified by Tollånes et al. for HbA1c 
(142). There are, however, several concerns identified toward introducing POC in the 
primary healthcare setting (112). Some of the issues, such as concerns with the 
accuracy of the POC tests and quality management, are usually addressed by 
performing IQC and participating in EQA schemes. In a total quality management 
system, like Noklus, the participants are offered help and guidance when needed. For 
the EQA organization to have knowledge of which factors are important for good 
quality is therefore essential and was addressed in this thesis.  
The MPs used in POC testing range from small benchtop MPs, which in practice are 
small-scale laboratory MPs, to small handheld portable MPs (20). Benchtop MPs are 
commonly used in GP offices, and the analyses are performed during the daytime by a 
limited number of operators. In contrast, the handheld MPs are used in a wide variety 
of settings, at all hours, and by the operator at work. In the study in paper II, the GP 
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offices achieved better performance than the other participants on the analysis usually 
performed using benchtop analyzers, whereas the nursing homes showed the best 
performance when performing the glucose analysis, normally performed using 
handheld MPs. At the GP offices one is more likely to find laboratory-qualified people 
employed. Laboratory training may reduce preanalytical factors because of knowledge 
of how to prepare the patient and how to perform sample collection and analytical 
factors by performing IQC and calibration. Errors in the postanalytical phase are often 
linked to the organizational settings and may not be related to laboratory education to 
the same extent. The fact that the nursing homes achieved the best quality when 
performing the glucose POC testing may be explained by the setting. Because 
glucometers are mainly used for self-monitoring, the test is more likely to be performed 
by staff at a nursing home than at a GP office. Performing the analysis frequently, 
which was another key factor associated with good performance, may, therefore, 
explain why nursing homes perform better than other participants in this context.  
Performing IQC on a weekly basis was a key factor associated with good performance. 
IQC, similar to EQA, is an essential component of quality management in laboratory 
testing. As IQC is essential for detecting, reducing, and correcting errors in the 
analytical phase in real time, it is not surprising that performing IQC frequently, is 
associated with good performance in EQA schemes. Finally, as expected, the MP used 
was of great importance for the quality of POC testing. The MPs differ both in 
analytical quality and user-friendliness, which are of great importance for the POC MPs 
as they are used under changing locations often by non-laboratory operators. Noklus, 
together with the Scandinavian evaluation of laboratory equipment for point of care 
testing (SKUP), evaluates and recommends POC MPs for primary care (143). The 
studies included in the present thesis can inform the participants of the importance of 
choosing the right MP and the importance of performing IQC frequently.  
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5.2.2 Commutability of the EQA control material 
Usually, processed or lyophilized EQA materials are used in EQA schemes as they 
have several attributes relevant to EQA providers. Examples of such attributes are large 
number of analytes that can be pooled together, these analytes are cost-effective and 
have excellent stability, which makes the material suitable for storage for later EQA 
schemes (67). However, matrix effects may interfere in the processed samples, thereby 
making them noncommutable (144, 145). To provide the participants with EQA 
samples that resemble native patient samples as much as possible is the aim of several 
EQA organizers, including Noklus. Different studies have addressed the importance of 
commutability in recent years, and many organizations have started evaluating the 
commutability of their materials. However, the studies are mainly assessing the 
commutability of reference materials being used as common calibrators, or the 
materials evaluated are chiefly serum or processed materials (127, 129, 146-148).  
This study is, by our knowledge, the first to show results of a non-hemolyzed whole 
blood EQA material which has been stable during the entire analytical period and also 
been commutable.  
A classification of EQA schemes into categories, depending on how well they can 
assess performance of the participants and MPs, was suggested earlier by Miller (55). 
Three essential characteristics of the EQA scheme are crucial for categorization, 
whereas the commutability of the EQA material is the most important. Before the 
commutability studies were conducted, all EQA schemes at Noklus were classified into 
category 5. As the commutability of the EQA material had not been evaluated, the 
schemes were limited to a peer-group assessment. Because of the bias between MPs, it 
was not possible to assess as the peer-group target value might be influenced by matrix 
effects (3). The results from the commutability study showed commutability for all 
CRP and Hb MPs, and because the CRP measurement is traceable to a CRM, and the 
Hb analysis has traceability to the HiCN reference method, a true common target value 
can now be calculated for these analytes (94, 101). Thus, participants using POC MPs 
for which the EQA material is commutable can now be classified in EQA category 1. 
Because the commutable EQA material, in theory, should have the same results for all 
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MPs and lots, the observed differences reflect real differences between the MPs used. 
In category 1, the participants can get an evaluation of the trueness and precision of 
their EQA result and the MP used, the reproducibility can be evaluated, and the EQA 
result can be used for standardization and harmonization efforts to achieve uniformity 
among MPs (55). Determining the EQA material’s commutability is a considerable 
advantage for the EQA organization, the participants, and the IVD industry as it 
provides for more adequate guidance as to how true analytical differences between the 
MPs can be detected. Distributing commutable EQA materials is also essential for the 
standardization and harmonization efforts currently taking place. The results from the 
EQA scheme will provide information regarding the true errors and differences 
between MPs, and the EQA organizations then have a unique position to conduct 
surveillance of the harmonization efforts and also be able to detect analytes in need of 
harmonization (149). Such a harmonization was, for example, seen for apolipoprotein 
A-I after the development of an international reference material and a standardization 
program which enabled traceability. The national EQA scheme could, following the 
harmonization, confirm a significant reduction in interlaboratory variation from 35% 
to 10% (146). 
For glucose, the commutability study revealed a differentiated response on the whole 
blood EQA material. Similar observations regarding glucose MPs have also been seen 
in other studies (122). For about half of the MPs that showed commutability at all 
concentrations, a true value can be calculated. The participants using these glucose 
POC MPs could then get their EQA results assessed compared to a true value. One 
cannot, however, expect all participants to have detailed knowledge regarding the 
commutability of the EQA material and how it influences the calculation of the target 
value. To explain why different target values are used for the same analyte can, 
therefore, be challenging. As a result, a peer-group target value is still used in the 
Noklus EQA scheme for glucose. However, Noklus calculates the systematic deviation 
from the true target value for the POC MPs for which the EQA material showed 
commutability. The information is available for IVD manufacturers and participants if 
needed and is also used by Noklus to provide recommendations on which MPs to use 
e.g., in screening for gestational diabetes (76). 
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An additional finding in the commutability study of glucose was that all analytes 
showed commutability at the lowest concentration. A similar result was demonstrated 
in a commutability study of a CRM for HbA1c by Liu et al. (127), in which in the two 
cases where the material was assessed noncommutable, it was at high concentrations. 
The finding emphasizes two crucial issues. The first is the importance of including 
more than one concentration when assessing a reference or EQA material. In the study 
in paper III, three CRP and glucose concentrations and two Hb concentrations were 
examined. The present study showed that inclusion of several EQA samples at different 
concentrations is of utmost importance as commutability at one concentration does not 
naturally denote commutability at other concentrations. 
The EP14-A3 guideline does not provide any recommendations regarding the number 
of EQA material concentrations to be assessed (108). The results from our study, 
nevertheless, bring attention to the need for a consensus on the number of 
concentrations in which the EQA materials need to be tested, which is also discussed 
in the new IFCC recommendations (86, 110). The IFCC recommendations suggest, 
however, that each concentration should be evaluated separately as commutable or 
noncommutable (13). For reference materials, the primary function of which is to act 
as a calibrator, this is reasonable. For EQA organizations, however, it would be an 
advantage having pre-agreed numbers of EQA samples needed to be commutable for 
the EQA material overall to be considered commutable. This evolves from the fact that 
it is practically impossible for the EQA organization to assess every possible 
concentration of an EQA material. Additionally, even if the organization aimed to 
distribute similar concentrations of the EQA material in consecutive schemes, the 
concentrations would always vary somewhat. The results from our study, therefore, 
highlight the importance of performing studies on the guidelines’ intended target 
group, in this case, the EQA providers’ EQA material, as the results from 
commutability testing of reference material do not automatically apply for EQA 
materials.  
The second issue is the noncommutability observed at higher concentrations. This 
finding might be caused by the abovementioned statistical limitation, or it may be 
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related to the concentration of the analyte. Although the study conducted by Liu et al. 
(127) did not specify whether the reference material was spiked, the EQA material 
produced by Noklus, and used in paper III, was spiked with human CRP and D(+)-
glucose monohydrate, which was the only feature varying between the low and high 
concentrations of the EQA material. Supplementation, although with highly purified 
human analytes, is known to possibly cause impurities (150, 151). 
In the study in paper III, the EQA material tested was a whole-blood EQA material 
customized by Noklus. The results from the study may, therefore, not be generalizable 
to other EQA materials produced in a different manner. The learnings from the study, 
however, can be useful for others when assessing the commutability of their material, 
either using the CLSI guideline step by step, like we did for CRP and Hb, or in a tailored 
procedure like that performed for glucose.  
By distributing a commutable EQA material to the participants, harmonization among 
different analytes and laboratories can be assessed. In an international context, this is 
related to standardization and harmonization of laboratory results, whereas locally, it 
is related to the patients being treated with the potential benefit of making transitions 
between primary and secondary care safer and more trouble free. Finally, large lot 
variations have been observed for different analytes. When a commutable material is 
distributed to the participants, the variation seen between lots of the reagents of the 
MPs in the EQA material will also be present for different lots of clinical samples and 
can therefore have clinical implications. 
 
5.3 Further research 
Additional research on POC testing taking a broader perspective is required. When 
using POC rather than central laboratory testing, the advantages must outweigh the 
challenges. In a systematic review on GPs attitudes toward POC testing, some main 
concerns were identified, including the POC test’s impact on clinical decisions and 
how it would affect clinical staff and workflow, issues related to cost, and regulation 
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and management of the quality of POC testing (152). Paper I and II in the current thesis 
addressed the quality management of POC testing, focusing on EQA. There is, 
however, little evidence on when to use IQC in POC testing, and further research could 
help determine when and how frequently IQC should be performed. Regarding quality 
management, the main focus has been on reducing errors in the analytical phase. 
Evaluation of the risk of errors in the entire testing process is, however, important. As 
seen in paper II of this thesis, which MP the participants used was a significant 
predictor for good quality. The POC MP will probably be even more important as they 
get more sophisticated, and functions for reducing both pre- and postanalytical errors 
are added. Research on whether choosing such MPs could affect the quality of POC 
testing would therefore be of great interest. Additionally, there is evidence that 
indicates serious failures in the way laboratory results are followed up, thus reflecting 
errors in the post- and post-postanalytical phase (153). How test results are evaluated 
and acted upon is key for best practice in diagnoses and management of patients and 
could be addressed in further research. However, as the nature of medical errors is 
multi-factorial, both people and system factors must, therefore, be addressed. 
It is important that results obtained from observational studies are translated into 
meaningful improvement efforts in clinical practice. The research should ideally lead 
to the development of clinical guidelines, policy changes, or better patient outcomes. 
The outcome measures in current studies, including paper I and II in this thesis, can be 
a somewhat distant measure for actual patient outcome. Different clinical outcomes to 
be studied further, in which some naturally depend on the setting where POC testing is 
used, could be whether POC improves adherence to treatment, whether treatment is 
decided and started earlier, or if there is a reduction in reoperation and readmission rate 
and reduced incidence of complications or mortality rates. Economical outcomes of 
POC testing should also be considered because laboratory tests can already be 
performed in well-functional laboratories, and it is not given that rapid test results lead 
to savings. Potential economic benefits to be considered can, for instance, be reduced 
hospital admissions, better and less inappropriate drug use, reduction of staff and 
equipment, or improved life quality. There are currently few studies on POC testing 
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addressing safety, efficiency, sustainability, or the economics of primary care in this 
context (154). Well-designed studies aiming to detect whether quality in the POC 
testing process affects clinical and economical outcomes are, therefore, needed.  
There has been improvement regarding the harmonization and standardization of 
laboratory test results. However, efforts to reduce interlaboratory variability should be 
prioritized. A key in achieving standardization is traceability and commutability. As 
seen in paper III of this thesis, commutability of the EQA material was determined for 
some analytes whereas for others, in our case, glucose, commutability was only 
determined for about half of the POC MPs. Further work on guidelines on how to assess 
commutability for different materials is, therefore, needed. In the case of EQA 
materials, further research on when an EQA material overall is commutable, i.e., how 
many concentrations of the material needs to be evaluated and how many of the 
evaluated samples must be commutable, needs to be assessed. In addition, how often 
an EQA material, produced in the same manner, should be reevaluated for 
commutability is of great importance because the EQA organization cannot assess 
commutability prior to every EQA scheme. There is also a need for further research on 
the commutability of both reference and EQA materials to achieve comparable results 
among MPs. Making the results comparable is important for developing clinical 
guidelines, which in turn are important for patient care related decisions. 
 
5.4 Conclusion 
In this thesis, we aimed to evaluate the effect of participating in an EQA organization 
and to evaluate the MPs and EQA material used to improve the participants’ analytical 
quality.  
The results from paper I and II, showed an increase in good participant performance 
and a decrease in poor participant performance depending on the number of years the 
participants took part in the Noklus quality improvement system. In addition, paper II 
showed that performing IQC weekly, performing the specific analysis ten or more 
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times weekly, using recommended MPs, and having laboratory-qualified operators 
predicted good participant performance in the EQAs. The results were, overall, similar 
for u-albumin, CRP, glucose, and Hb.  
The results from paper III, showed that the whole-blood EQA material produced at 
Noklus was commutable for all CRP and Hb POC MPs and for about half of the glucose 
POC MPs used in primary health care in Norway. Consequently, a common reference 
value can be used to assess the participants’ and Hb results. For glucose, all participant 
results were evaluated using method-specific target values. Because a commutable 
EQA material and reference values can be applied, the possibility to discover true 
analytical errors is improved, and consequently, possible errors in the treatment of 
patients and disease management can more likely be prevented. In addition, true 
systematic differences between the POC MPs can be discovered. This gives the EQA 
organizations’ an opportunity to provide IVD manufactures feedback and also improve 
the guidance to participants on which MP to use. By having a commutable EQA 
material, the EQA organizations can monitor the degree of, and analytes in need of, 
standardization and harmonization.  
In conclusion, systematic participation in quality management for POC testing in 
primary health care can improve the analytical quality of u-albumin, CRP, Hb, and 
glucose measurements. The whole-blood EQA material used was commutable for all 
CRP and Hb MPs and about half the glucose MPs used in primary healthcare in 
Norway. For these participants and MPs, both participant and MP evaluation can now 
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Point-of-care urine albumin in general practice 
offices: effect of participation in an external 
quality assurance scheme
Abstract
Background: The Norwegian Quality Improvement of 
Primary Care Laboratories (Noklus) offers external quality 
assurance (EQA) schemes (EQASs) for urine albumin (UA) 
annually. This study analyzed the EQA results to deter-
mine how the analytical quality of UA analysis in general 
practice (GP) offices developed between 1998 (n = 473) and 
2012 (n = 1160).
Methods: Two EQA urine samples were distributed yearly 
to the participants by mail. The participants measured the 
UA of each sample and returned the results together with 
information about their instrument, the profession and 
number of employees at the office, frequency of internal 
quality control (IQC), and number of analyses per month. 
In the feedback report, they received an assessment of 
their analytical performance.
Results: The number of years that the GP office had par-
ticipated in Noklus was inversely related to the percent-
age of “poor” results for quantitative but not semiquan-
titative instruments. The analytical quality improved for 
participants using quantitative instruments who received 
an initial assessment of “poor” and who subsequently 
changed their instrument. Participants using reagents 
that had expired or were within 3 months of the expira-
tion date performed worse than those using reagents that 
were expiring in more than 3 months.
Conclusions: Continuous participation in the Noklus pro-
gram improved the performance of quantitative UA analy-
ses at GP offices. This is probably in part attributable to 
the complete Noklus quality system, whereby in addition 
to participating in EQAS, participants are visited by labo-
ratory consultants who examine their procedures and pro-
vide practical advice and education regarding the use of 
different instruments.
Keywords: external quality assurance schemes; point-of-
care testing; primary health care; urine albumin.
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Introduction
Diabetic nephropathy occurs in 20%–40% of patients with 
diabetes mellitus [1]. Urine albumin (UA) is a well-estab-
lished marker for chronic kidney disease with or without 
diabetes and plays an important role in its early diagnosis, 
assessment, and treatment [1–3]. UA has also been shown 
to be an important marker for cardiovascular disease [4–
7]. Measurements of albumin excretion may be performed 
in timed collections, early morning urine, or random 
urine collections. It is, however, recommended that early 
morning void and expression of results as albumin/cre-
atinine ratio (ACR) are used [8]. For clinicians to be able 
to detect UA and begin to intervene when necessary, they 
need an analytically reliable result. Quality assurance 
of UA is therefore essential to ensure that laboratories 
provide reliable results. The Norwegian Quality Improve-
ment of Primary Care Laboratories (Noklus) is responsi-
ble for external quality assurance (EQA) in Norway and 
has since 1992 offered EQA schemes (EQASs) for most of 
the analytes analyzed in primary health care. UA is part 
of the EQA program at Noklus, as well as in several other 
EQA programs worldwide [9]. It has been reported that the 
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EQAS is important for improving analytical quality [10]; 
however, there is little documented information or evi-
dence supporting this assumption.
The present study analyzed the results of the EQAS, 
with the aim of determining how the analytical quality of 
UA analysis in the general practice (GP) offices in Norway 
developed between 1998 and 2012 in relation to the length 
of the participants’ involvement in EQA and to evaluate 




During the period 1998–2012, 15 UA EQASs were distributed to GP 
offices in Norway; the total percentage of GP offices participating 
voluntarily in the Noklus quality assurance system, including par-
ticipation in EQASs for the constituents that they analyze, is 99.7%. 
The GPs buy their own instruments; the point-of-care (POC) semi-
quantitative instruments used between 1998 and 2012 were Clinitek 
Status+, Clinitek Status, Clinitek 50, and Clinitek 100 (Siemens 
Healthcare Diagnostics), and MICRAL-TEST (Roche Diagnostics), 
whereas the quantitative instruments were Afinion AS100 Analyzer 
and NycoCard U-Albumin (Axis-Shield PoC), DCA 2000 Analyzer, 
DCA 2000+ Analyzer, and DCA Vantage Analyzer (Siemens Health-
care Diagnostics), HemoCue Urine Albumin and HemoCue Albu-
min 201 (HemoCue), and QuikRead U-ALB and QuikRead101 (Orion 
Diagnostica).
EQA survey
The EQA material was obtained by mixing samples from volunteers 
with normal or increased excretion of UA to achieve appropriate con-
centrations of UA. Noklus collected the samples before each survey 
and stored them at –80 °C. A few of the samples were stored for up 
to 2 years before they were circulated. The samples were sterile fil-
tered prior to their circulation. They were then distributed at room 
temperature by mail, and the participants were instructed to keep 
them refrigerated after receiving them. Each GP office received two 
EQA samples containing albumin at two different concentrations. 
During the study period (i.e., 1998–2012), the concentration of albu-
min ranged from about 15 to 130 mg/L, with the mean for the low- and 
high-concentration samples being 27 and 78 mg/L, respectively. The 
participants analyzed each EQA sample on two different days (1 × 2 
design) when quantitative methods were used and on one day (1 × 1 
design) when semiquantitative methods were used.
The participants returned the analytical results within 6  days 
of the mailing day. The EQA samples were, according to the ISO 
13528, stable and homogeneous during this period [9, 11]. The par-
ticipants also provided information about the POC instrument, the 
lot number and expiration date of the reagents used, the numbers of 
general practitioners and their coworkers at the GP office, the educa-
tion level of the person who usually performed the UA analysis, how 
often internal quality control (IQC) was performed, and the number 
of UA analyses performed monthly. Only results concerning UA are 
reported in the present article, as only DCA instruments were used to 
measure ACR throughout the whole study period.
Assessment
Trueness was defined in this study as closeness of the mean of dupli-
cate measurements and the method-specific target value; precision 
was calculated as the difference between duplicate measurements; 
and accuracy was defined as closeness of the agreement between a 
measured quantity value and the method-specific target value. These 
definitions are modified from those in the International Vocabulary 
of Metrology [12].
Although a candidate reference method has been suggested [13], 
the combination of no reference method being accepted in the period 
of the study and the freezing of the EQA samples, which might lead 
to matrix effects and non-commutability between the methods [14], 
method-specific target values were used. For the quantitative meth-
ods, the target value was a “trimmed” median, calculated for instru-
ment groups containing  ≥  20 participants after excluding outliers 
that were more than  ± 3 SDs from the median. The semiquantitative 
instruments reported their results in one of four possible categories, 
and the categories with  > 30% of the semiquantitative answers were 
set as the target value.
For quantitative instruments, each EQA sample was analyzed 
twice, and the participants received assessments (“very good”, “accept-
able”, and “poor”) concerning trueness and precision for each of the 
two levels. For semiquantitative instruments, the samples were ana-
lyzed once, and feedback on accuracy (“good”, “questionable”, and 
“poor”) was provided for each of the two levels. Table 1 lists the qual-
ity specifications used by Noklus for quantitative and semiquantitative 
methods. The quality specifications are much stricter for quantitative 
methods than for semiquantitative methods. Examples on how these 
quality specifications are calculated are given in online Supplemental 
Data, Table 1, that accompanies the article at http://www.degruyter.
com/view/j/cclm.2015.53.issue-1/issue-files/cclm.2015.53.issue-1.xml.
When analyzing results from both EQA samples together, the 
following categories were used for quantitative methods:
1. “Very good” trueness/precision: Participants obtaining “very 
good” trueness/precision assessments on both EQA samples.
2. “Acceptable” trueness/precision: Participants that obtained 
“acceptable” trueness/precision assessment on one EQA sample 
and “acceptable” or “very good” trueness/precision on the other.
3. “Poor” trueness/precision: All the other participants.
Similarly, the following categories were used when evaluating par-
ticipants using semiquantitative instrument:
1. “Good” accuracy: Participants obtaining “good” accuracy 
assessments on both EQA samples.
2. “Questionable” accuracy: Participants that obtained “question-
able” accuracy on one EQA sample and “questionable” or “very 
good” trueness on the other.
3. “Poor” accuracy: All the other participants.
The GP offices are defined as “new”, both when they participate in 
the EQASs for the first time and when they change from a semiquan-
titative to a quantitative instrument; otherwise, they are defined as 
“old”.
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Table 1 Noklus quality specifications for assessing trueness, precision, and accuracy in the UA EQA.a
  Quality specifications
Quantitative instruments  
Target interval   Within  ± 2 mg/L of the method-specific target value
Trueness  
 Very good   Mean value of duplicate measurements within  ± 7%
 Acceptable   Mean value of duplicate measurements within target  ± 15%
 Poor   Mean value of duplicate measurements outside  ± 15%
Precision  
 Very good   Difference between duplicate measurements:  ≤  target value lower limit for “very good” trueness
 Acceptable   Difference between duplicate measurements: values between “very good” and “poor” precision
 Poor   Difference between duplicate measurements: target value lower limit for “acceptable” trueness
Semiquantitative instruments 
 Accuracy  
  Good   The categories with  > 30% of the answers
  Questionable   The “neighboring” categories
  Poor   The remaining categories
aExamples on how this is calculated is given in Supplemental data Table 1.
The influence of the expiration date on the participants’ assess-
ments was evaluated. Participants using the Afinion instruments 
were excluded from the group using expired reagents because this 
instrument does not accept reagents with an expired date.
Statistics
The two-sided χ2-test and Fisher’s exact test were used to determine 
whether there were significant differences between the odds ratios 
(ORs). The level of statistical significance was set at p < 0.05. Testing 
for binominal proportions was used to explore the effects of chang-
ing an instrument and to determine any significant changes in prac-
tice characteristics between 1998 and 2012.
Logistic regression was applied to each EQA survey. Dependent 
variables were the trueness and precision of the assessments, and 
the independent variables were the instrument used, profession of 
the person who performed the analysis, frequency of IQC, number of 
GP employees at the office (until 2006), and number of analyses per 
month (from 2009). The data were analyzed using SPSS version 19.0.
Results
The percentage of GP offices analyzing UA and participat-
ing in the UA Noklus EQAS, relative to the total number of 
Norwegian GP offices, increased from 26% (473/1809) in 
1998 to 68% (1163/1723) in 2012. Semiquantitative instru-
ments were used by 76% in 1998 but only 9% in 2012 (see 
Supplemental Data, Figure 1). Figures 1A and 2A show the 
percentage of GP offices that achieved “very good”/“good” 
or “poor” assessments relative to the year of the EQA 
survey. From 1998 to 2003, the percentage of GP offices 
with assessments “very good” trueness (quantitative) and 
“good” accuracy (semiquantitative) decreased from 92% 
to 67% and from 86% to 58% for quantitative and semi-
quantitative instruments, respectively. After 2003, the 
percentage with assessments of “very good” trueness or 
“good” accuracy increased, then stabilized at 75%–90%.
Figures 1B and 2B show the percentage of GP offices 
obtaining “very good”/“good” or “poor” assessments rel-
ative to the number of years they have participated in the 
Noklus EQA program. The percentage of GP offices obtain-
ing an assessment of “poor” trueness using a quantitative 
instrument decreased the longer they had participated in 
the EQAS. A similar decrease was not seen for semiquan-
titative instruments.
Comparing “old” to “new” participants using quan-
titative instruments, the OR for being assessed as “very 
good” trueness rather than “poor” in general increased 
with the number of years that the GP office had partici-
pated in the EQAS [i.e., comparison of participating for the 
third and ninth times yielded ORs of 1.5, 95% confidence 
interval (CI) 1.1–2.1, and 4.2, 95% CI: 2.2–7.8, respectively]. 
Regarding the precision, significantly more “old” par-
ticipants compared to “new” participants were assessed 
as “very good” compared with “poor” (OR, 1.5, 95% CI, 
1.2–1.8). “Old” participants using only a quantitative DCA 
instrument (DCA 2000, DCA 2000+, or DCA Vantage) were 
analyzed separately to eliminate possible effects of chang-
ing instruments. “Old” participants performed signifi-
cantly better than “new” participants concerning trueness 
(OR, 2.0, 95% CI, 1.3–3.3)] but not precision.
The mean values of the instruments used in surveys 
have differed, as exemplified by the survey in 2012 where 
the UA at the low concentration was 33.6 mg/L (95% 
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Figure 2 Semiquantitative instruments: percentage of participants that achieved “good” assessments (solid black line) and “poor” 
assessments (dashed black line) relative to the year of the EQA survey (A) or the number of years of participation in Noklus (B).
Year 1 includes GP offices participating for the first time using semiquantitative instruments (n = 635). Year 15 includes GP offices participat-
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Figure 1 Quantitative instruments: percentage of participants that achieved “very good” assessments (solid black line) and “poor” 
 assessments (dashed black line) relative to the year of the EQA survey (A) or the number of years of participation in Noklus (B).
Year 1 includes GP offices participating for the first time using quantitative instruments (n = 1249). Year 15 includes GP offices participating 
in 15 EQASs using quantitative instruments (n = 19).
CI, 33.4–33.8) for the DCA instruments, compared with 
30.8 mg/L (95% CI, 30.6–31.1) and 34.7 mg/L (95% CI, 34.4–
34.9) for the Afinion and HemoCue instruments (HemoCue 
Urine Albumin and HemoCue Albumin 201), respectively.
Changing instruments
Participants using quantitative instruments that received 
an assessment of “poor” trueness and subsequently 
changed their instrument received significantly fewer 
“poor” assessments the following year, regardless of 
whether they changed to another type of the same instru-
ment or to a different type of quantitative instrument, 
compared with those who did not change instrument. 
When participants with an initial assessment of “very 
good” trueness changed to a different instrument, signifi-
cantly fewer participants received “very good” trueness 
assessments, compared with when the participants did 
not change instrument (Table 2). Similar results were not 
found for participants using semiquantitative instruments 
(results not shown).
Several practice characteristics changed sig-
nificantly between 1998 and 2012. For example, the 
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Table 2 Effect on analytical quality of changing to a different POC instrument.
  “Poor” trueness, n   “Poor” trueness the 
following year, n (%, 95% CI)
Total number of participants with “poor” trueness   199   49 (25)
Changing to a different POC instrument the following year   29   3 (10, 0–20)
Not changing to a different POC instrument the following year   170   46 (27, 21–33)
  “Very good” trueness, n   “Very good” trueness the 
following year, n (%, 95% CI)
Total number of participants with “very good” trueness   3784   3627 (96)
Changing to a different POC instrument the following year   151   138 (91, 88–94)
Not changing to a different POC instrument the following year   3633   3489 (96, 96–97)
percentage of GP offices never performing IQC decreased 
from 48% to 6% (p < 0.001), and the percentage of par-
ticipants using the DCA instruments increased from 
24% to 42% (p < 0.001), whereas the percentage using 
MICRAL-TEST decreased from 71% to 2% (p < 0.001). The 
DCA line (including all DCA instruments on the market at 
the time of the study) performed better than each of the 
other quantitative instruments regarding both trueness 
and precision in more than 70% of the surveys (see Sup-
plemental Data, Table 2). The profession of the person 
who performed the analysis, the frequency of IQC, the 
number of general practitioners at the GP office, and the 
number of analyses per month did not influence the par-
ticipants’ assessments.
Expiration date of the reagents
Participants using semiquantitative instruments used 
expired reagents significantly more often than those 
using quantitative instruments: 13% vs. 2%. Concern-
ing quantitative instruments, GP offices using reagents 
with more than 3 months to expiration performed signifi-
cantly better than those using reagents expiring within 
3  months (p < 0.001) or using reagents that had already 
expired (p < 0.001). Similar findings were not seen for 
participants using semiquantitative instruments (results 
not shown).
Discussion
The value of participating in EQA programs has been 
emphasized by several organizations [15, 16], and in 
some countries, such participation is also mandatory [17]. 
Although participating in POC EQA programs is voluntary 
in Norway, 99.7% of Norwegian GP offices are enrolled in 
the program.
The effects of participating in EQA programs are diffi-
cult to quantify, and few studies have addressed the issue. 
However, one study found that the between-laboratory var-
iation can decrease as the number of years participating in 
EQA programs increases [18], and another study found that 
circulating calibrators from EQA organizers can decrease 
the between-laboratory variation [19]. In the present study, 
we showed that the number of years a GP office had par-
ticipated in Noklus, using quantitative instrument, was 
inversely related to the percentage of “poor” results. The 
same trend was not found for participants using semi-
quantitative instruments (Figures 1B and 2B).
Noklus offers not only an EQAS, but also an overall 
quality assurance system for laboratories in primary 
health care. In addition to the EQAS, this includes labora-
tory consultants visiting the GP offices providing courses 
and advice and distributing recommendations from the 
Scandinavian Evaluation of Laboratory Equipment for 
Primary Health Care [20]. With respect to the individual 
guidance performed by Noklus, the EQAS is the key for 
detecting which GP offices need additional help and edu-
cation. That the improvement in analytical quality is due 
not only to the change in instrument is exemplified by 
the DCA line (DCA 2000, DCA 2000+, and DCA Vantage), 
whereby the trend to improve is present even when the 
same instrument brand is used. Upgrades of DCA instru-
ments should not influence the improvement seen in the 
DCA line, as such upgrades mainly pertain to the instru-
ments’ software [21].
Participation in Noklus influences when a GP office 
chooses to change its instruments because laboratory 
consultants visit and offer advise about what instrument 
to buy. This advice is based on study of literature, SKUP 
evaluations [20], and performance in the EQA.
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For quantitative instruments, analytical quality 
improved for participants who were initially assessed 
as “poor” and subsequently changed their instrument 
to a new version or to a different brand. Similar results 
have been observed when changing tests for infectious 
mono nucleosis [22]. Participants that initially received 
an assessment of “very good” and then changed to a 
new instrument type did not improve their analytical 
quality. This suggests that participants performing well 
should usually not change the instrument they are 
using. It is a positive trend that most participants cur-
rently choose quantitative instruments for analyzing 
UA (see Supplemental Data, Figure 1). Early on, Noklus 
advised GP offices to use quantitative instruments and 
have now recommended that the Norwegian govern-
ment should not reimburse for semiquantitative UA 
tests.
Although the performance characteristics of both 
quantitative and semiquantitative instruments have 
improved in recent years (Figures 1A and 2A), it is 
important to bear in mind that due to the wider quality 
specifications, the performance of semiquantitative 
instruments is not in any way comparable with that of 
quantitative instruments (see Supplemental Data, Table 
1). This may explain why we did not find that partici-
pants using such instruments benefit from participating 
in an EQAS to the same extent as those using quantita-
tive instruments.
The DCA instruments yielded especially good results 
in the present study: DCA instruments performed sig-
nificantly better than the other instruments as shown by 
logistic regression analysis (see Supplemental Data, Table 
2), which is in line with reports from other studies [23–25]. 
The present study also showed that use of IQC in GP offices 
has increased, which is encouraging because maintaining 
day-to-day consistency is important for obtaining reliable 
analytical results.
We found that participants using reagents expiring in 
more than 3  months performed significantly better than 
those using expired or nearly expired reagents. Similar 
findings have been reported for reagents for POC infec-
tious mononucleosis [22]. The UA analysis is performed 
relatively seldom (47% of GP offices performed  ≤  10 analy-
ses/week in Norway in 2012) and studies have found that 
GP offices do not screen for microvascular complications 
as often as desired [26–31]. This may cause manufacturers 
to extend the expiration date of the reagents. Other poten-
tial reasons like inappropriate storage or transport condi-
tions may also contribute.
A limitation of the present study is that method-spe-
cific target values had to be used because the samples 
were kept at –80 °C a few days, or in a few cases up to 
2 years, before the survey. Freezing could affect the UA 
methods in different ways [14], but studies indicate that 
the effects are probably not dependent upon the length 
of the freezing period [9, 32–35]. Thus, it is not possible 
to state unequivocally whether the differences between 
the mean values for the different methods are due to 
non-commutability or to “real” differences between 
the methods. However, there is currently no reference 
method or reference material for UA, making a “true” 
trueness evaluation impossible, although a candidate 
reference method and reference materials for UA has 
recently been developed [13]. Another limitation of the 
present study was that only UA and not ACR results were 
determined because only one instrument brand reported 
ACR throughout the entire study period. However, this is 
unlikely to have greatly altered the results because the 
assessments of UA and ACR were consistent in about 
90% of the cases (results not shown). A major strength 
of the present study is that it includes data from a long 
period and from almost all Norwegian GP offices using 
the same type of EQA samples. Thus, all of the instru-
ments measuring UA on the Norwegian market during 
that period were included, as were several changes in 
reagent lot numbers.
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Table 1. Noklus criteria for assessing trueness, precision and accuracy in the UA EQA. 
 Criterion 
Quantitative instruments  
Target interval Within 2 mg/L of the method–specific target value 
Trueness  
Very good Mean value of duplicate measurements within 7% 
Acceptable Mean value of duplicate measurements within target 15% 
Poor Mean value of duplicate measurements outside 15% 
Precision  
Very good Difference between duplicate measurements: target value lower 
limit for “very good” trueness 
Acceptable Difference between duplicate measurements: values between “very 
good” and “poor” precision 
Poor Difference between duplicate measurements: target value lower limit 





Good The categories with >30% of the answers  
Questionable The “neighboring” categories 
Poor The remaining categories 
Quantitative instruments Example 
Target value 30 mg/L 
Target interval 28–32 mg/L 
Trueness  
Very good 26 (28  0.93) – 34.2 (32  1.07) mg/L 
Acceptable 23.8 (28  0.85) –25.9 mg/L or 34.3 – 36.8 (32  1.15) mg/L  
Poor <23.8 (28  0.85) mg/L or >36.8 (32  1.15) mg/L 
Precision  
Very good Difference between duplicate measurements ≤4 (30– 26) mg/L 
Acceptable Difference between duplicate measurement range: 4.1– 6.2 mg/L 





Target value 30 mg/L (possible categories 10/30/80/150 mg/L) 
Accuracy  
Good The category “30 mg/L”. The interval ranging from 20 to 55mg/L  
Questionable The category “10 mg/L” and “80 mg/L”. The interval ranging from 
0 to 19 mg/L and from 56 to 115 mg/L 






Table 2. Results from logistic regression concerning trueness and precision*.  
   Trueness Precision 
POC instrument     
DCA all Better than NycoCard Reader II 9/9 9/9 
DCA all Better than  QuikRead all 5/7 5/7 
DCA all Better than HemoCue Urine 
Albumin 
6/8 6/8 
DCA all Better than HemoCue 201 6/7 6/7 
DCA all Better than Afinion 5/6 6/6 
Afinion  Better than  HemoCue 201 3/6  
Number of EQA surveys with significantly better trueness and precision compared to number 
of EQA surveys where both instruments were included (number of participants >10). Only 
significant differences occurring in 50% of the surveys have been included. DCA all 
includes the DCA 2000, DCA 2000+ and DCA Vantage instruments. QuikRead all includes 
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